PT J
AU Zheng, GD
   Sayama, K
   Okubo, T
   Juneja, LR
   Oguni, I
AF Zheng, GD
   Sayama, K
   Okubo, T
   Juneja, LR
   Oguni, I
TI Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice
SO IN VIVO
LA English
DT Article
DE green tea powder; catechins; caffeine; theanine; fat accumulation; lipid metabolism; anti-obesity
ID energy-expenditure; fat oxidation; food-intake; human volunteers; blood-pressure; oolong tea; rats; cholesterol; catecholamines; thermogenesis
AB To elucidate the anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, female ICR mice were fed on diets containing 2% green tea powder and diets containing 0.3% catechins, 0.05% caffeine and 0.03% theanine, which correspond, respectively, to their concentrations in a 2% green tea powder diet, singly and in combination for 16 weeks. Body weight and food intake were determined monthly during this period, kidneys, adrenals, liver, spleen, brain, pituitary and intraperitoneal adipose tissues (IPAT) were weighed and lipid levels in the serum and liver were measured at the end of this period. The body weight increase and weight of IPA T were significantly reduced by the diets containing green tea, caffeine, theanine, caffeine + catechins, caffeine + theanine and caffeine + catechins + theanine. Noticeably, the IPA T weight decreased by 76.8% in the caffeine + catechins compared to the control group. Serum concentrations of triglycerides (TG) and non-esterified fatty acids (NEFA) were decreased by green tea, catechins and theanine. Moreover, caffeine + catechins, caffeine + theanine and caffeine + catechins + theanine also decreased NEFA in the serum. The TG level in the liver was significantly reduced by catechins and catechins + theanine in comparison with the control. These results indicated that at least caffeine and theanine were responsible for the suppressive effect of green tea powder (GTP) on body weight increase and fat accumulation. Moreover, it was shown that catechins and caffeine were synergistic in anti-obesity activities.
C1 Univ Shizuoka, Fac Agr, Dept Appl Biol Chem, Shizuoka 4228529, Japan.
   Taiyo Kagaku Co Ltd, Cent Res Labs, Yokaichi 5100844, Japan.
   Univ Shizuoka, Sch Food & Nutrit Sci, Shizuoka 4228526, Japan.
C3 University of Shizuoka; TAIYO KAGAKU CO., LTD.; University of Shizuoka
RP Univ Shizuoka, Fac Agr, Dept Appl Biol Chem, 836 Ohya, Shizuoka 4228529, Japan.
EM acksaya@agr.shizuoka.ac.jp
CR Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881
   ARCIERO PJ, 1995, AM J PHYSIOL-ENDOC M, V268, PE1192, DOI 10.1152/ajpendo.1995.268.6.E1192
   BARTLETT GR, 1959, J BIOL CHEM, V234, P466
   Bina KG, 2000, NEUROENDOCRINOLOGY, V71, P68, DOI 10.1159/000054522
   CAO Y, 1999, NATURE, V398, P0
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   FLETCHER MJ, 1968, CLIN CHIM ACTA, V22, P393, DOI 10.1016/0009-8981(68)90041-7
   FOLCH J, 1957, J BIOL CHEM, V226, P479
   Fukuyo M, 1986, NIPPON EIYO SHOKURYO, V39, P495
   Han LK, 1999, INT J OBESITY, V23, P98, DOI 10.1038/sj.ijo.0800766
   HARA Y, 1989, NIPPON EIYO SHOKURYO, V42, P39
   IKEDA I, 1992, BIOCHIM BIOPHYS ACTA, V1127, P141, DOI 10.1016/0005-2760(92)90269-2
   JUNG RT, 1981, CLIN SCI, V60, P527, DOI 10.1042/cs0600527
   Kakuda T, 2000, BIOSCI BIOTECH BIOCH, V64, P287, DOI 10.1271/bbb.64.287
   Kao Y, 2000, AM J CLIN NUTR, V72, P1232
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Kobayashi K, 1998, NIPPON NOGEIK KAISHI, V72, P153
   Kono S, 1996, J EPIDEMIOL, V6, P128
   MATSUZAKI T, 1985, J AGR CHEM SOC JPN, V59, P129, DOI 10.1271/nogeikagaku1924.59.129
   MURAMATSU K, 1986, J NUTR SCI VITAMINOL, V32, P613, DOI 10.3177/jnsv.32.613
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Oguni I, 1989, JAPANESE JOURNAL OF NUTRITION, V47, P93
   OKUDA T, 1984, CHEM PHARM BULL, V32, P3755
   RACOTTA IS, 1994, PHARMACOL BIOCHEM BE, V48, P887, DOI 10.1016/0091-3057(94)90196-1
   ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   Sayama K, 2000, IN VIVO, V14, P481
   Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534
   Takeo T, 1992, TEA: CULTIVATION TO CONSUMPTION, V0, PP413, DOI 10.1007/978-94-011-2326-6_13
   TOWELL A, 1988, PHARMACOL BIOCHEM BE, V30, P641, DOI 10.1016/0091-3057(88)90077-9
   Valcic S, 1996, ANTI-CANCER DRUG, V7, P461, DOI 10.1097/00001813-199606000-00011
   Watanabe J, 1998, BIOSCI BIOTECH BIOCH, V62, P532, DOI 10.1271/bbb.62.532
   Yokogoshi H, 1998, BIOSCI BIOTECH BIOCH, V62, P816, DOI 10.1271/bbb.62.816
   YOKOGOSHI H, 1995, BIOSCI BIOTECH BIOCH, V59, P615, DOI 10.1271/bbb.59.615
   Yokogoshi H, 1998, NEUROCHEM RES, V23, P667, DOI 10.1023/A:1022490806093
   ZAK B, 1957, AM J CLIN PATHOL, V27, P583, DOI 10.1093/ajcp/27.5_ts.583
NR 39
TC 235
Z9 282
U1 0
U2 74
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD JAN-FEB 15
PY 2004
VL 18
IS 1
BP 55
EP 62
DI 
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 777DW
UT WOS:000189161100008
PM 15011752
DA 2025-04-28
ER

PT J
AU Greenway, FL
   de Jonge, L
   Blanchard, D
   Frisard, M
   Smith, SR
AF Greenway, FL
   de Jonge, L
   Blanchard, D
   Frisard, M
   Smith, SR
TI Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition
SO OBESITY RESEARCH
LA English
DT Article
DE ephedra; caffeine; metabolic rate; body composition; herbal dietary supplement
ID catechin-polyphenols; energy-expenditure; obese women; green tea; efficacy; safety; thermogenesis; exercise
AB Objective: To evaluate the effect of a dietary supplement containing herbal caffeine (70 mg/dose) and ephedra (24 mg/dose; C&E) on metabolic rate, weight loss, body composition, and safety parameters. Research Methods and Procedures: In phase 1, 12 healthy subjects with a BMI of 25 to 35 kg/m 2 had resting metabolic rate (RMR) measured for 2 hours after ingesting C&E or a placebo on two occasions I week apart, followed by a 1-week washout before phase II. In phase 11, these 12 and 28 additional subjects were randomized to a 12-week, double-blind trial comparing C&E (3 times/day) to placebo. In phase III, the C&E group was given open-label C&E for 3 months, and the placebo group was given C&E for 6 months. Results: In phase 1, C&E gave an average 8 +/- 0.1% (SE) rise, in RMR over 2 hours compared with placebo (p < 0.01). In phase 11, weight loss at 12 weeks was 3.5 +/- 0.6 kg with C&E compared with 0.8 +/- 0.5 kg with placebo (p < 0.02). The percentage fat lost, shown by DXA, was 7.9 +/- 2.9% with C&E and 1.9 +/- 1.1% with placebo (p < 0.05). Pulse decreased more. in the placebo group that in the CE group (p < 0.03). There were no differences in lipid levels or blood pressure. In phase 111, there was a 6-month loss of 7.3% and 7.8% of initial body weight for the groups on placebo and C&E during phase 11, respectively. There were no serious adverse events. Discussion: C&E increased RMR significantly by 8% compared with placebo, promoted more weight and fat loss than placebo, and was well tolerated.
C1 Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
C3 Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center
RP Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.
EM greenwfl@pbrc.edu
CR ASTRUP A, 1992, INT J OBESITY, V16, P269
   Boozer CN, 2001, INT J OBESITY, V25, P316, DOI 10.1038/sj.ijo.0801539
   Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023
   Dowling EA, 1996, MED SCI SPORT EXER, V28, P482, DOI 10.1097/00005768-199604000-00013
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   *FDC, 2000, FDC REP, V0, P0
   Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541
   GOODMAN L, 1985, PHARMACOL BASIS THER, V0, P595
   Greenway F L, 2001, OBES REV, V2, P199, DOI 10.1046/j.1467-789x.2001.00038.x
   HAGAN RD, 1982, INT J SPORTS MED, V3, P177, DOI 10.1055/s-2008-1026085
   Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502
   Hoeger WWK, 1998, ADV THER, V15, P305
   JAEDIG S, 1994, MINER ELECTROL METAB, V20, P147
   LIU YL, 1995, INT J OBESITY, V19, P678
   MALCHOWMOLLER A, 1981, INT J OBESITY, V5, P183
   Pi-Sunyer FX, 1998, OBES RES, V6, P0
   ROGERS PJ, 1994, PHYSIOL BEHAV, V56, P247, DOI 10.1016/0031-9384(94)90191-0
   SCHECHTER PJ, 1979, AM J CLIN NUTR, V32, P1011, DOI 10.1093/ajcn/32.5.1011
   Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537
   Umeta M, 2000, LANCET, V355, P2021, DOI 10.1016/S0140-6736(00)02348-5
   Vansal SS, 1999, BIOCHEM PHARMACOL, V58, P807, DOI 10.1016/S0006-2952(99)00152-5
   Volpe SL, 2001, J AM COLL NUTR, V20, P293, DOI 10.1080/07315724.2001.10719050
NR 23
TC 53
Z9 59
U1 0
U2 19
PU NORTH AMER ASSOC STUDY OBESITY
PI SILVER SPRING
PA 8630 FENTON ST, SUITE 918, SILVER SPRING, MD 20910 USA
SN 1071-7323
EI 
J9 OBES RES
JI Obes. Res.
PD JUL 15
PY 2004
VL 12
IS 7
BP 1152
EP 1157
DI 10.1038/oby.2004.144
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 844KY
UT WOS:000223158300015
PM 15292480
DA 2025-04-28
ER

PT J
AU Beauvois, MC
   Arredouani, A
   Jonas, JC
   Rolland, JF
   Schuit, F
   Henquin, JC
   Gilon, P
AF Beauvois, MC
   Arredouani, A
   Jonas, JC
   Rolland, JF
   Schuit, F
   Henquin, JC
   Gilon, P
TI Atypical Ca<SUP>2+</SUP>-induced Ca<SUP>2+</SUP> release from a sarco-endoplasmic reticulum Ca<SUP>2+</SUP>-ATPase 3-dependent Ca<SUP>2+</SUP> pool in mouse pancreatic β-cells
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID inositol 1,4,5-trisphosphate receptor; rapid cooling contractures; induced calcium-release; ryanodine receptor; insulin-secretion; 2-aminoethoxydiphenyl borate; cardiac myocytes; skeletal-muscle; cyclic-amp; a7r5 cells
AB The contribution of Ca2+ release from intracellular stores to the rise in the free cytosolic Ca2+ concentration ([Ca2+](c)) triggered by Ca2+ influx was investigated in mouse pancreatic beta-cells. Depolarization of beta-cells by 45 mM K+ (in the presence of 15 mM glucose and 0.1 mM diazoxide) evoked two types of [Ca2+](c) responses: a monotonic and sustained elevation; or a sustained elevation superimposed by a transient [Ca2+](c) peak (TCP) (40-120 s after the onset of depolarization). Simultaneous measurements of [Ca2+](c) and voltage-dependent Ca2+ current established that the TCP did not result from a larger Ca2+ current. Abolition of the TCP by thapsigargin and its absence in sarco-endoplasmic reticulum Ca2+-ATPase 3 (SERCA3) knockout mice show that it is caused by Ca2+ mobilization from the endoplasmic reticulum. A TCP could not be evoked by the sole depolarization of beta-cells but required a rise in [Ca2+](c) pointing to a Ca2+-induced Ca2+ release (CICR). This CICR did not involve inositol 1,4,5-trisphosphate (IP3) receptors (IP(3)Rs) because it was resistant to heparin. Nor did it involve ryanodine receptors (RyRs) because it persisted after blockade of RyRs with ryanodine, and was not mimicked by caffeine, a RyR agonist. Moreover, RyR1 and RyR2 mRNA were not found and RyR3 mRNA was only slightly expressed in purified beta-cells. A CICR could also be detected in a limited number of cells in response to glucose. Our data demonstrate, for the first time in living cells, the existence of an atypical CICR that is independent from the IP3R and the RyR. This CICR is prominent in response to a supraphysiological stimulation with high K+, but plays little role in response to glucose in non-obese mouse pancreatic beta-cells.
C1 Univ Louvain, Fac Med, Unite Endocrinol & Metab, Brussels, Belgium.
   Free Univ Brussels, Diabet Res Ctr, Brussels, Belgium.
C3 Universite Catholique Louvain; Universite Libre de Bruxelles
RP Univ Louvain, Fac Med, Unite Endocrinol & Metab, Brussels, Belgium.
EM gilon@endo.ucl.ac.be
CR Arredouani A, 2002, DIABETES, V51, P3245, DOI 10.2337/diabetes.51.11.3245
   Arredouani A, 2002, AM J PHYSIOL-ENDOC M, V282, PE982, DOI 10.1152/ajpendo.00347.2001
   ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8
   Bak J, 2002, BIOCHEM BIOPH RES CO, V295, P806, DOI 10.1016/S0006-291X(02)00761-1
   Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2
   Barg S, 2001, BIOPHYS J, V81, P3308, DOI 10.1016/S0006-3495(01)75964-4
   Barg S, 2000, DIABETES, V49, P1500, DOI 10.2337/diabetes.49.9.1500
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927
   BERS DM, 1989, J PHYSIOL-LONDON, V417, P537, DOI 10.1113/jphysiol.1989.sp017817
   BERS DM, 1987, CAN J PHYSIOL PHARM, V65, P610, DOI 10.1139/y87-103
   Bers DR, 1999, CARDIOVASC RES, V42, P339, DOI 10.1016/S0008-6363(99)00038-3
   BIDEN TJ, 1987, J BIOL CHEM, V262, P3567
   Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709
   De Backer F, 2002, J PHYSIOL-LONDON, V542, P855, DOI 10.1113/jphysiol.2002.020487
   De Smet P, 1999, CELL CALCIUM, V26, P9
   Dyachok O, 2004, CELL CALCIUM, V36, P1, DOI 10.1016/j.ceca.2003.11.004
   EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4
   FOURNIER L, 1994, J BIOL CHEM, V269, P1120
   Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0
   Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902
   Gamberucci A, 1999, FEBS LETT, V446, P309, DOI 10.1016/S0014-5793(99)00220-3
   Gilon P, 1999, J BIOL CHEM, V274, P20197, DOI 10.1074/jbc.274.29.20197
   GILON P, 1992, J BIOL CHEM, V267, P20713
   GRAPENGIESSER E, 1991, J BIOL CHEM, V266, P12207
   Gromada J, 1996, BIOCHEM J, V314, P339, DOI 10.1042/bj3140339
   Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751
   Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147
   ISLAM MS, 1995, BIOCHEM J, V306, P679, DOI 10.1042/bj3060679
   Islam MS, 2002, DIABETES, V51, P1299, DOI 10.2337/diabetes.51.5.1299
   Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145
   Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749
   Johnson JD, 2004, FASEB J, V18, P878, DOI 10.1096/fj.03-1280fje
   Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112
   Jonkers FC, 1999, J PHYSIOL-LONDON, V520, P839, DOI 10.1111/j.1469-7793.1999.00839.x
   Kasri NN, 2003, J BIOL CHEM, V278, P27548, DOI 10.1074/jbc.M302026200
   Lee B, 2001, BIOCHEM PHARMACOL, V61, P327, DOI 10.1016/S0006-2952(00)00559-1
   Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200
   Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538
   Liu YJ, 1996, ARCH BIOCHEM BIOPHYS, V334, P295, DOI 10.1006/abbi.1996.0458
   LLANO I, 1994, NEURON, V12, P663, DOI 10.1016/0896-6273(94)90221-6
   LUND PE, 1994, N-S ARCH PHARMACOL, V349, P503, DOI 10.1007/BF00169140
   Macianskiene R, 2002, AM J PHYSIOL-HEART C, V282, PH1879, DOI 10.1152/ajpheart.00952.2001
   Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498
   Missiaen L, 2001, CELL CALCIUM, V29, P111, DOI 10.1054/ceca.2000.0163
   Murayama T, 2002, TRENDS CARDIOVAS MED, V12, P305, DOI 10.1016/S1050-1738(02)00179-2
   NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067
   NILSSON T, 1988, FEBS LETT, V229, P211, DOI 10.1016/0014-5793(88)80829-9
   Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298
   PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806
   Ravier MA, 2002, DIABETOLOGIA, V45, P1154, DOI 10.1007/s00125-002-0883-9
   Rolland JF, 2002, DIABETES, V51, P376, DOI 10.2337/diabetes.51.2.376
   Rorsman P, 2000, NEWS PHYSIOL SCI, V15, P72
   RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7
   Satin LS, 2000, ENDOCRINE, V13, P251, DOI 10.1385/ENDO:13:3:251
   SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335
   SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584
   Shmigol A, 1995, J PHYSIOL-LONDON, V489, P627, DOI 10.1113/jphysiol.1995.sp021078
   SMITH GL, 1988, J GEN PHYSIOL, V92, P351, DOI 10.1085/jgp.92.3.351
   Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027
   Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497
   Tengholm A, 1998, DIABETES, V47, P1224, DOI 10.2337/diabetes.47.8.1224
   Tengholm A, 1999, J BIOL CHEM, V274, P36883, DOI 10.1074/jbc.274.52.36883
   TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506
   Wissing F, 2002, BIOCHEM J, V361, P605, DOI 10.1042/0264-6021:3610605
   WORLEY JF, 1994, J BIOL CHEM, V269, P14359
   Wuytack F, 2002, CELL CALCIUM, V32, P279, DOI 10.1016/S0143416002001847
   Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164
NR 68
TC 26
Z9 30
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD AUG 15
PY 2004
VL 559
IS 1
BP 141
EP 156
DI 10.1113/jphysiol.2004.067454
PG 16
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 849XK
UT WOS:000223574700013
PM 15218077
DA 2025-04-28
ER

PT J
AU Thompson, OM
   Ballew, C
   Resnicow, K
   Must, A
   Bandini, LG
   Cyr, H
   Dietz, WH
AF Thompson, OM
   Ballew, C
   Resnicow, K
   Must, A
   Bandini, LG
   Cyr, H
   Dietz, WH
TI Food purchased away from home as a predictor of change in BMI z-score among girls
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE children; adolescents; quick-service food; BMI; overweight
ID body-mass index; obesity; epidemic; children; dietary; women
AB OBJECTIVES: To assess the relationship between eating food purchased away from home (FAH) and longitudinal change in body mass index (BMI) z-score among girls, and to assess the longitudinal tracking of eating FAH from childhood through adolescence. DESIGN: Participants kept 7-day dietary records at two points in time. The records included the place and time for all foods consumed. We recorded how often participants ate FAH, calculated the percent of total energy derived from FAH, and classified foods as quick-service food, coffee-shop food, or restaurant food. PARTICIPANTS: Healthy girls (n = 101) between the ages of 8 and 12 y at baseline and 11 and 19 y at follow-up participated in a longitudinal study of growth and development at the Massachusetts Institute of Technology. STATISTICAL ANALYSES: Analysis of variance was used to assess the relationship between change in BMI z-score and both the frequency of eating FAH and energy derived from eating FAH. The participants' baseline BMI z-score was a significant covariate and was controlled for in both models. We used the kappa coefficient to assess FAH tracking from childhood through adolescence. RESULTS: The frequency of eating quick-service food at baseline was positively associated with change in BMI z-score (F = 6.49, P < 0.01). Participants who ate quick-service food twice a week or more at baseline had the greatest mean increase in BMI z-score compared to those who ate quick-service food once a week or not at all. Quick-service food eating tracked slightly from childhood through adolescence (k = 0.17, P < 0.05). DISCUSSION: Adolescent girls who eat quick-service food twice a week or more are likely to increase their relative BMI over time.
C1 Univ Washington, Dept Nutr Sci, Seattle, WA 98195 USA.
   Alaska Nat Epidemiol Ctr, Anchorage, AK USA.
   Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA.
   Tufts Univ, Sch Med, Dept Family Med & Community Hlth, Boston, MA 02111 USA.
   Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA.
   UMASS, Sch Med, Eunice Kennedy Shriver Ctr, Waltham, MA USA.
   MIT, Clin Res Ctr, Cambridge, MA 02139 USA.
   Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA USA.
C3 University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; Tufts University; Boston University; Eunice Kennedy Shriver Center; Massachusetts Institute of Technology (MIT); Centers for Disease Control & Prevention - USA
RP Univ Washington, Dept Nutr Sci, 305 Raitt Hall,Box 353410, Seattle, WA 98195 USA.
EM omt@u.washington.edu
FU NCRR NIH HHS [M01-RR-00088] Funding Source: Medline; NIDDK NIH HHS [DK46200, R01-DK50537] Funding Source: Medline
CR BANDINI LG, 1995, AM J CLIN NUTR, V62, P711, DOI 10.1093/ajcn/62.4.711
   Baranowski T, 2000, PREV MED, V31, PS1, DOI 10.1006/pmed.2000.0686
   Binkley JK, 2000, INT J OBESITY, V24, P1032, DOI 10.1038/sj.ijo.0801356
   BORRUD L, 1996, FOOD REV SEP, V0, P14
   Clauson A, 1999, FOODREVIEW, V22, P20
   Dietz WH, 1999, AM J CLIN NUTR, V70, P0
   FREEDMAN DS, 1900, V49, V0, P0
   French SA, 2001, ANNU REV PUBL HEALTH, V22, P309, DOI 10.1146/annurev.publhealth.22.1.309
   French SA, 2000, INT J OBESITY, V24, P1353, DOI 10.1038/sj.ijo.0801429
   Glantz SA, 1997, PRIMER OF BIOSTATISTICS, V0, P0
   Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371
   Jeffery RW, 1998, AM J PUBLIC HEALTH, V88, P277, DOI 10.2105/AJPH.88.2.277
   Jekanowski MD, 1999, FOODREVIEW, V22, P11
   LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786
   LIN BH, 1999, AGR INFORMATION B US, V749, P0
   McCrory MA, 1999, OBES RES, V7, P564, DOI 10.1002/j.1550-8528.1999.tb00715.x
   Must A, 1999, INT J OBESITY, V23, PS2, DOI 10.1038/sj.ijo.0800852
   MUST A, 1991, AM J CLIN NUTR, V53, P839, DOI 10.1093/ajcn/53.4.839
   Nestle M, 2000, PUBLIC HEALTH REP, V115, P12, DOI 10.1093/phr/115.1.12
   Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728
   PENNINGTON JA, 1997, BOWES CHURCHDS FOOD, V0, P0
   SAS Institute Inc, 1999, SAS STAT US GUID VER, V0, P0
   Young LR, 2002, AM J PUBLIC HEALTH, V92, P246, DOI 10.2105/AJPH.92.2.246
NR 28
TC 155
Z9 212
U1 0
U2 8
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD FEB 15
PY 2004
VL 28
IS 2
BP 282
EP 289
DI 10.1038/sj.ijo.0802538
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 765VH
UT WOS:000188304700014
PM 14647177
DA 2025-04-28
ER

PT J
AU Acheson, KJ
   Gremaud, G
   Meirim, I
   Montigon, F
   Krebs, Y
   Fay, LB
   Gay, LJ
   Schneiter, P
   Schindler, C
   Tappy, L
AF Acheson, KJ
   Gremaud, G
   Meirim, I
   Montigon, F
   Krebs, Y
   Fay, LB
   Gay, LJ
   Schneiter, P
   Schindler, C
   Tappy, L
TI Metabolic effects of caffeine in humans: lipid oxidation or futile cycling?
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE paraxanthine; slow-release caffeine; thermic effect; lipid turnover; oxidative lipid disposal; nonoxidative lipid disposal
ID ephedrine-induced thermogenesis; free fatty-acids; energy-expenditure; obese women; coffee; carbohydrate; paraxanthine; epinephrine; volunteers; ingestion
AB Background: Caffeine ingestion stimulates both lipolysis and energy expenditure. Objectives: Our objectives were to determine whether the lipolytic effect of caffeine is associated with increased lipid oxidation or futile cycling between triacylglycerol and free fatty acids (FFAs) and whether the effects of caffeine are mediated via the sympathetic nervous system. Design: Respiratory exchange and [1-C-13] palmitate were used to trace lipid oxidation and FFA turnover in 8 healthy, young men for 90 min before and 240 min after ingestion of placebo, caffeine (10 mg/kg), or caffeine during beta-adrenoceptor blockade. Results: During fasting conditions, there were few differences in measured variables between the 3 tests. During steady state conditions (last hour of the test) after ingestion of caffeine, lipid turnover increased 2-fold (P < 0.005), and the mean (+/-SEM) thermic effect was 13.3 +/- 2.2% (P < 0.001), both of which were greater than after ingestion of placebo or caffeine during beta-adrenoceptor blockade. After ingestion of caffeine, oxidative FFA disposal increased 44% (236 +/- 21 to 340 +/- 16 mumol/min), whereas nonoxidative FFA disposal increased 2.3-fold (455 +/- 66 to 1054 +/- 242 mumol/min; P < 0.01). In postabsorptive conditions, 34% of lipids were oxidized and 66% were recycled. Caffeine ingestion increased energy expenditure 13% and doubled the turnover of lipids, of which 24% were oxidized and 76% were recycled. beta-Adrenoceptor blockade decreased, but did not inhibit, these variables. Conclusions: Many, but not all, of the effects of caffeine are mediated via the sympathetic nervous system. The effect of caffeine on lipid mobilization in resting conditions can be interpreted in 2 ways: lipid mobilization alone is insufficient to drive lipid oxidation, or large increments in lipid turnover result in small increments in lipid oxidation.
C1 Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland.
   Inst Physiol, Lausanne, Switzerland.
   Univ Lausanne Hosp, Cent Pharm, Lausanne, Switzerland.
C3 Nestle SA; Nestle Research Center; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)
RP Acheson, KJ (corresponding author), Nestle Res Ctr, POB 44,Vers Chez Blanc, CH-1000 Lausanne 26, Switzerland.
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   ARCIERO PJ, 1995, AM J PHYSIOL-ENDOC M, V268, PE1192, DOI 10.1152/ajpendo.1995.268.6.E1192
   ARNAUD MJ, 1981, METHODS CLIN PHARM, V3, P135
   ASTRUP A, 1991, METABOLISM, V40, P323, DOI 10.1016/0026-0495(91)90117-F
   ASTRUP A, 1992, METABOLISM, V41, P686, DOI 10.1016/0026-0495(92)90304-S
   ASTRUP A, 1986, AM J PHYSIOL, V250, PE226, DOI 10.1152/ajpendo.1986.250.2.E226
   ASTRUP A, 1985, AM J PHYSIOL, V248, P507
   BELLET S, 1969, METABOLIS, V18, P288, DOI 10.1016/0026-0495(69)90049-3
   BELLET S, 1968, METABOLISM, V17, P702, DOI 10.1016/0026-0495(68)90054-1
   Benowitz NL, 1995, CLIN PHARMACOL THER, V58, P684, DOI 10.1016/0009-9236(95)90025-X
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   BREITENSTEIN E, 1990, BURNS, V16, P259, DOI 10.1016/0305-4179(90)90136-K
   BUTCHER RW, 1968, J BIOL CHEM, V243, P1705
   Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999
   Denborough M, 1998, LANCET, V352, P1131, DOI 10.1016/S0140-6736(98)03078-5
   DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315
   DULLOO AG, 1986, INT J OBESITY, V10, P467
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   DULLOO AG, 1987, AM J CLIN NUTR, V45, P564, DOI 10.1093/ajcn/45.3.564
   GROOP LC, 1991, J CLIN INVEST, V87, P83, DOI 10.1172/JCI115005
   HETZLER RK, 1990, J APPL PHYSIOL, V68, P44, DOI 10.1152/jappl.1990.68.1.44
   Higgins HL, 1915, J PHARMACOL EXP THER, V7, P1
   ISSEKUTZ B, 1968, METABOLISM, V17, P62, DOI 10.1016/S0026-0495(68)80008-3
   JEQUIER E, 1987, ANNU REV NUTR, V7, P187, DOI 10.1146/annurev.nu.07.070187.001155
   KLEIN S, 1989, AM J PHYSIOL, V257, PE65, DOI 10.1152/ajpendo.1989.257.1.E65
   LEVITZKI A, 1988, SCIENCE, V241, P800, DOI 10.1126/science.2841758
   LIU YL, 1995, INT J OBESITY, V19, P678
   LIVESEY G, 1988, AM J CLIN NUTR, V47, P608, DOI 10.1093/ajcn/47.4.608
   MILLS PR, 1984, GUT, V25, P73, DOI 10.1136/gut.25.1.73
   SCHNECK DW, 1984, CLIN PHARMACOL THER, V36, P584, DOI 10.1038/clpt.1984.225
   SCHWARZ JM, 1992, AM J PHYSIOL, V262, PE591, DOI 10.1152/ajpendo.1992.262.5.E591
   SCHWARZ JM, 1989, THESIS U LAUSANNE SW, V0, P0
   SIDOSSIS LS, 1995, AM J PHYSIOL-ENDOC M, V269, PE649, DOI 10.1152/ajpendo.1995.269.4.E649
   Wolfe RR, 1984, TRACERS IN METABOLIC RESEARCH: RADIOISOTOPE AND STABLE ISOTOPE/MASS SPECTOMETRY METHODS, V0, P0
   WOLFE RR, 1980, BIOMED MASS SPECTROM, V7, P168, DOI 10.1002/bms.1200070407
   WOLFE RR, 1990, AM J PHYSIOL, V258, PE382, DOI 10.1152/ajpendo.1990.258.2.E382
   WOLFE RR, 1987, NEW ENGL J MED, V317, P403, DOI 10.1056/NEJM198708133170702
   ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857
NR 39
TC 144
Z9 163
U1 0
U2 50
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA
SN 0002-9165
EI 
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JAN 15
PY 2004
VL 79
IS 1
BP 40
EP 46
DI 
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 757NZ
UT WOS:000187569500007
PM 14684395
DA 2025-04-28
ER

PT J
AU Saper, RB
   Eisenberg, DM
   Phillips, RS
AF Saper, RB
   Eisenberg, DM
   Phillips, RS
TI Common dietary supplements for weight loss
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID body-fat mass; chromium picolinate; acid; metaanalysis; overweight; reduction; chitosan; efficacy; glucose; ephedra
AB Over-the-counter dietary supplements to treat obesity appeal to many patients who desire a "magic bullet" for weight loss. Asking overweight patients about their use of weight-loss supplements and understanding the evidence for the efficacy, safety, and quality of these supplements are critical when counseling patients regarding weight loss. A schema for whether physicians should recommend, caution, or discourage use of a particular weight-loss supplement is presented in this article. More than 50 individual dietary supplements and more than 125 commercial combination products are available for weight loss. Currently, no weight-loss supplements meet criteria for recommended use. Although evidence of modest weight loss secondary to ephedra-caffeine ingestion exists, potentially serious adverse effects have led the U.S. Food and Drug Administration to ban the sale of these products. Chromium is a popular weight-loss supplement, but its efficacy and long-term safety are uncertain. Guar gum and chitosan appear to be ineffective; therefore, use of these products should be discouraged. Because of insufficient or conflicting evidence regarding the efficacy of conjugated linoleic acid, ginseng, glucomannan, green tea, hydroxycitric acid, L-carnitine, psyllium, pyruvate, and St. John's wort in weight loss, physicians should caution patients about the use of these supplements and closely monitor those who choose to use these products. Copyright (C) 2004 American Academy of Family Physicians.
C1 Harvard Univ, Sch Med, Div Res & Educ Complementary & Integrat Med Thera, Boston, MA 02115 USA.
   Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.
C3 Harvard University; Harvard Medical School; Harvard University; Harvard University Medical Affiliates; Beth Israel Deaconess Medical Center
RP Saper, RB (corresponding author), Boston Univ, Sch Med, Dept Family Med, 1 Boston Med Ctr Pl,Dowling 5 S, Boston, MA 02118 USA.
EM robert.saper@bmc.org
FU NCCIH NIH HHS [K24 AT00589-02, T32 AT00051] Funding Source: Medline
CR Althuis MD, 2002, AM J CLIN NUTR, V76, P148, DOI 10.1093/ajcn/76.1.148
   Anderson RA, 1997, DIABETES, V46, P1786, DOI 10.2337/diabetes.46.11.1786
   Anderson RA, 1998, NUTR REV, V56, P266, DOI 10.1111/j.1753-4887.1998.tb01763.x
   Armanini D, 2003, J ENDOCRINOL INVEST, V26, P646, DOI 10.1007/BF03347023
   Bahadori B, 1997, ACTA MED AUST, V24, P185
   Bent S, 2003, ANN INTERN MED, V138, P468, DOI 10.7326/0003-4819-138-6-200303180-00010
   Blanck HM, 2001, JAMA-J AM MED ASSOC, V286, P930, DOI 10.1001/jama.286.8.930
   Blankson H, 2000, J NUTR, V130, P2943, DOI 10.1093/jn/130.12.2943
   Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023
   Cairella M, 1995, CLIN TER, V146, P269
   Cerulli J, 1998, ANN PHARMACOTHER, V32, P428, DOI 10.1345/aph.17327
   Crawford V, 1999, DIABETES OBES METAB, V1, P331, DOI 10.1046/j.1463-1326.1999.00055.x
   DEBUSK RM, 2001, INTEGRATIVE MED CONS, V3, P30
   Delany JP, 1999, AM J PHYSIOL-REG I, V276, PR1172, DOI 10.1152/ajpregu.1999.276.4.R1172
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Ernst E, 1998, PERFUSION, V11, P461
   *FDA, 1981, FDA CONS, V0, P3
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Gades MD, 2003, OBES RES, V11, P683, DOI 10.1038/oby.2003.97
   Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502
   Heymsfield SB, 1998, JAMA-J AM MED ASSOC, V280, P1596, DOI 10.1001/jama.280.18.1596
   Ho SC, 2001, SMJ SINGAPORE MEDICAL JOURNAL, V42, P006
   Kalman D, 1999, NUTRITION, V15, P337, DOI 10.1016/S0899-9007(99)00034-9
   LEUNG LH, 1995, MED HYPOTHESES, V44, P403, DOI 10.1016/0306-9877(95)90268-6
   LOWENSTEIN JM, 1971, J BIOL CHEM, V246, P629
   Martin WR, 1998, PHARMACOTHERAPY, V18, P860
   Mattes RD, 2000, PHYSIOL BEHAV, V71, P87, DOI 10.1016/S0031-9384(00)00321-8
   *MED EC CO, 2000, PHYS DESK REF HERB M, V0, P0
   Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728
   Pasman WJ, 1997, INT J OBESITY, V21, P1143, DOI 10.1038/sj.ijo.0800528
   Pittler MH, 2001, AM J MED, V110, P724, DOI 10.1016/S0002-9343(01)00702-1
   Pittler MH, 1999, EUR J CLIN NUTR, V53, P379, DOI 10.1038/sj.ejcn.1600733
   Rodriguez-Moran M, 1998, J DIABETES COMPLICAT, V12, P273, DOI 10.1016/S1056-8727(98)00003-8
   SANSONE RA, 1984, AM FAM PHYSICIAN, V30, P141
   SCALI M, 1990, J ENDOCRINOL INVEST, V13, P847, DOI 10.1007/BF03349639
   Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537
   SOTANIEMI EA, 1995, DIABETES CARE, V18, P1373, DOI 10.2337/diacare.18.10.1373
   *US FDA, 2004, FDA ANN PLANS PROH S, V0, P0
   Vincent JB, 2003, SPORTS MED, V33, P213, DOI 10.2165/00007256-200333030-00004
   Vita P M, 1992, MINERVA MED, V83, P135
   WALSH DE, 1984, INT J OBESITY, V8, P289
   Weiger WA, 2002, ANN INTERN MED, V137, P889, DOI 10.7326/0003-4819-137-11-200212030-00010
   Wuolijoki E, 1999, METHOD FIND EXP CLIN, V21, P357, DOI 10.1358/mf.1999.21.5.793477
NR 44
TC 151
Z9 180
U1 0
U2 35
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD NOV 1
PY 2004
VL 70
IS 9
BP 1731
EP 1738
DI 
PG 8
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 869XB
UT WOS:000225016800014
PM 15554492
DA 2025-04-28
ER

PT J
AU Coffey, CS
   Steiner, D
   Baker, BA
   Allison, DB
AF Coffey, CS
   Steiner, D
   Baker, BA
   Allison, DB
TI A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE ephedra alkaloids; weight loss; BMI; safety; efficacy
ID weight-loss
AB OBJECTIVE: To evaluate the efficacy and side effects of an herbal formulation to promote weight loss, as compared to placebo. DESIGN: 12-week multicenter double-blind, placebo-controlled, randomized parallel groups design. Study conducted at three clinical sites in New York State. Subjects were randomized to receive either the 'active' product or a 'placebo' supplement for 12 weeks. Minimal steps were taken to influence lifestyle changes with regard to diet or exercise. SUBJECTS: 102 overweight/obese (30<BMI <= 39.9 kg/m(2)) volunteers between the ages of 18 and 65 y. MAIN OUTCOME MEASURES: Weight, percent body fat, fat mass, waist circumference, BMI, blood pressure, and pulse measured at 2 days, 1 week, 2 weeks, 4 weeks, 8 weeks, and 12 weeks postrandomization. RESULTS: Subjects receiving the 'active' treatment experienced, on average, an additional 1.5 kg of weight loss compared with subjects receiving the placebo. In addition, subjects receiving the 'active' treatment experienced greater reductions in BMI and waist circumference over the 12-week period. No differences were observed with respect to percent body fat, fat mass, diastolic or systolic blood pressure, pulse, the occurrence of any adverse event, or the occurrence of any presumed treatment-related adverse event. Testing of the study product by two independent laboratories indicated that it had only approximately half of the intended amount of ephedrine alkaloids and caffeine. CONCLUSIONS: Over the 12-week trial, subjects on the active treatment experienced significantly greater weight loss than subjects on placebo, without an increase in blood pressure, pulse, or the rate of adverse events. These benefits were achieved in the absence of any lifestyle treatment to change dietary or exercise behavior and with lower doses of ephedrine alkaloids and caffeine than those commonly utilized.
C1 Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA.
   Res Testing Labs, Great Neck, NY USA.
   Univ Alabama, Sect Stat Genet, Birmingham, AL 35294 USA.
   Univ Alabama, Clin Nutr Res Unit, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham
RP Univ Alabama, Dept Biostat, Ryals Publ Hlth Bldg 327,1665 Univ Blvd, Birmingham, AL 35294 USA.
EM Dallison@uab.edu
CR Allison D B, 1995, ENDOCR PRACT, V1, P353
   Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530
   Allison DB, 2001, CRIT REV FOOD SCI, V41, P1, DOI 10.1080/20014091091661
   ALLISON DB, 1999, WEIGHT CONTROL DIGES, V9, P827
   Unknown -, 2001, CAFFEINE FOR THE SUSTAINMENT OF MENTAL TASK PERFORMANCE: FORMULATIONS FOR MILITARY OPERATIONS, V0, P0
   Unknown -, 2003, AHRQ PUBLICATION, V0, P0
   ASTRUP A, 1991, METABOLISM, V40, P323, DOI 10.1016/0026-0495(91)90117-F
   ASTRUP A, 1992, INT J OBESITY, V16, P269
   Ayyad C, 2000, OBES REV, V1, P113, DOI 10.1046/j.1467-789x.2000.00019.x
   Bosello O, 2002, EAT WEIGHT DISORD, V7, P161
   DHURANDHAR N, 2000, EC NEUROSCI, V2, P42
   DULLOO AG, 1993, INT J OBESITY, V17, P0
   *EPH WORK GROUP, 2003, REP EPH WORK GROUP N, V0, P0
   *FDA, 2004, CONS AL FDA PLANS RE, V0, P0
   Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187
   Gadbury G L, 2003, OBES REV, V4, P175, DOI 10.1046/j.1467-789X.2003.00109.x
   GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397
   Greenway F L, 2001, OBES REV, V2, P199, DOI 10.1046/j.1467-789x.2001.00038.x
   GREENWAY FL, 2004, HDB OBESITY, V0, P329
   Gregg EW, 2003, ANN INTERN MED, V138, P383, DOI 10.7326/0003-4819-138-5-200303040-00007
   Gurley BJ, 2000, AM J HEALTH-SYST PH, V57, P963, DOI 10.1093/ajhp/57.10.963
   Haddock CK, 2002, INT J OBESITY, V26, P262, DOI 10.1038/sj.ijo.0801889
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/nejmoa012512
   Ku YR, 2003, J PHARMACEUT BIOMED, V33, P329, DOI 10.1016/S0731-7085(03)00287-5
   Littell RC, 1996, SAS SYSTEMS MIXED MO, V0, P0
   MALCHOWMOLLER A, 1981, INT J OBESITY, V5, P183
   National Taxicology Program, 1986, NATL. TOXICOL. PROGR. TECH. REP, V307, P1
   Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728
   PORTA M, 1986, ANN ALLERGY, V57, P340
   Yang D, 2003, OBES REV, V4, P9, DOI 10.1046/j.1467-789X.2003.00092.x
NR 30
TC 45
Z9 49
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD NOV 15
PY 2004
VL 28
IS 11
BP 1411
EP 1419
DI 10.1038/sj.ijo.0802784
PG 9
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 862FY
UT WOS:000224477200007
PM 15356670
DA 2025-04-28
ER

PT J
AU Gregg, EW
   Cadwell, BL
   Cheng, YJ
   Cowie, CC
   Williams, DE
   Geiss, L
   Engelgau, MM
   Vinicor, F
AF Gregg, EW
   Cadwell, BL
   Cheng, YJ
   Cowie, CC
   Williams, DE
   Geiss, L
   Engelgau, MM
   Vinicor, F
TI Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S
SO DIABETES CARE
LA English
DT Article
ID nutrition examination survey; impaired glucose-tolerance; us adults; coffee consumption; national-health; risk-factor; mellitus
AB OBJECTIVE - To examine trends in the prevalence of diagnosed and undiagnosed diabetes and the proportion of total cases previously diagnosed, according to obesity status in the U.S. over the past 40 years. RESEARCH DESIGN AND METHODS - We assembled data from five consecutive cross-sectional national surveys: National Health Examination Survey I (1960-1962), National Health and Nutrition Examination Survey (NHANES) I (1971-1974), NHANES II (1976-1980), NHANES III (1988-1994), and NHANES 1999-2000. Diagnosed diabetes was ascertained, and height and weight were measured in adults aged 20-74 years in all surveys. In NHANES II, NHANES III, and NHANES 1999-2000, a fasting glucose level greater than or equal to126 mg/dl was used to identify cases among individuals not reporting diabetes. Design-based analyses and Bayesian models estimate the probability that prevalence of diabetes increased within four BMI groups (<25, 25-29, 30-34, and greater than or equal to35 kg/m(2)). RESULTS - In the U.S. population aged 20-74 years between 1976-1980 and 1999-2000,, significant increases in the prevalence of diagnosed diabetes (3.3-5.8%, probability >99.9%) were accompanied by nonsignificant increases in undiagnosed diabetes (2.0-2.4%, 66.6%). This resulted in an increase in total diabetes (5.3 8.2%, >99.9%) and a modest nonsignificant increase in the proportion of cases that were diagnosed (62-70%, 62.4%). However, these trends varied considerably by BMI level. In individuals with BMI greater than or equal to35 kg/m(2), diagnosed diabetes increased markedly (from 4.9% in 1960, to 8.6% during 1976-1980, to 15.1% in 1999-2000; probability >99.9%), whereas undiagnosed diabetes declined considerably (12.5% during 1976-1980 to 3.2% in 1999-2000, probability of increase 4.5%) Therefore, the proportion of total diabetes cases that were diagnosed increased from 41 to 83% (probability 99.9%) among individuals with BMI greater than or equal to35 kg/m(2). By comparison, changes in prevalence within BMI strata <35 kg/m(2) were modest and there was no increase in the percent of total cases that were diagnosed. CONCLUSIONS - National surveys over the last several decades have found large increases in diagnosed diabetes, particularly in overweight and obese individuals, but this has been accompanied by large decreases in undiagnosed diabetes only among individuals with BMI greater than or equal to35 kg/m(2). This suggests that improvements in diabetes awareness and detection are most prominent among this subgroup.
C1 CDCP, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30341 USA.
   Northrop Grumman, Div Informat Technol, Atlanta, GA USA.
   NIDDK, NIH, Bethesda, MD USA.
C3 Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
RP CDCP, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, 4770 Buford Hwy,NE Mailstop K-10, Atlanta, GA 30341 USA.
EM edg7@cdc.gov
CR Borch-Johnsen K, 1998, BMJ-BRIT MED J, V317, P371
   *CDCP, 2003, PREV DIAGN DIAB AG U, V0, P0
   *CDCP, 1997, DIAB SURV, V0, P0
   COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001
   Desai Jay, 2003, J PUBLIC HEALTH MANAG PRACT, VSuppl, P0
   Fagot-Campagna A, 2000, J PEDIATR-US, V136, P664, DOI 10.1067/mpd.2000.105141
   FLEGAL KM, 1991, DIABETES CARE, V14, P628, DOI 10.2337/diacare.14.7.628
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Ford ES, 1997, AM J EPIDEMIOL, V146, P214, DOI 10.1093/oxfordjournals.aje.a009256
   Freid VM, 2003, CHARTBOOK ON TRENDS IN THE HEALTH OF AMERICANS. HEALTH, V0, P0
   Gelman A, 1995, BAYESIAN DATA ANAL, V0, P0
   HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523
   Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518
   Hu FB, 1999, AM J CLIN NUTR, V70, P1001
   Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492
   Imperatore G, 2004, AM J EPIDEMIOL, V160, P531, DOI 10.1093/aje/kwh232
   Jiang R, 2002, JAMA-J AM MED ASSOC, V288, P2554, DOI 10.1001/jama.288.20.2554
   Liu SM, 2000, AM J PUBLIC HEALTH, V90, P1409, DOI 10.2105/AJPH.90.9.1409
   Manson JE, 2000, AM J MED, V109, P538, DOI 10.1016/S0002-9343(00)00568-4
   MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63
   MCDOWELL A, 1981, VITAL HLTH STAT, V1, P15
   Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195
   Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278
   *MRC BIOST UN, 2003, WINBUGS, V0, P0
   *NAT CTR HLTH STAT, 2001, NHANES 1999 2000 DAT, V0, P0
   *NAT CTR HLTH STAT, 1973, VITAL HLTH STAT 1, V10, P1
   *NAT CTR HLTH STAT, 1965, VITAL HLTH STAT, V4, P1
   Pi-Sunyer FX, 1998, OBES RES, V6, P0
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   *SAS I, 1999, SAS PROC GUID, V0, P0
   Saydah SH, 2004, ANN EPIDEMIOL, V14, P507, DOI 10.1016/j.annepidem.2003.09.016
   SHAH B, 1999, SUDAAN USERS MANUAL, V0, P0
   STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
   1994, 1900, V32, V0, P1
NR 38
TC 249
Z9 295
U1 0
U2 9
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD DEC 15
PY 2004
VL 27
IS 12
BP 2806
EP 2812
DI 10.2337/diacare.27.12.2806
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 874DU
UT WOS:000225331900006
PM 15562189
DA 2025-04-28
ER

PT J
AU Halkjær, J
   Sorensen, TIA
   Tjonneland, A
   Togo, P
   Holst, C
   Heitmann, BL
AF Halkjær, J
   Sorensen, TIA
   Tjonneland, A
   Togo, P
   Holst, C
   Heitmann, BL
TI Food and drinking patterns as predictors of 6-year BMI-adjusted changes in waist circumference
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE abdominal obesity; food patterns; prospective study; waist circumference
ID body-mass index; to-hip ratio; coronary-heart-disease; adipose-tissue distribution; life-style factors; whole-grain intake; middle-aged men; dietary patterns; physical-activity; cardiovascular-disease
AB Few studies have investigated the prospective associations between diet or drinking patterns and abdominal obesity; we therefore investigated whether food and beverage groups or patterns predicted 6-year changes in waist circumference (WC) and whether these associations were independent of concurrent changes in BMI as a measure of general obesity. The subjects were 2300 middle-aged men and women with repeated measurements of dietary intake, BMI and WC from 1982 to 1993. Intakes from ten food groups and from coffee, tea, wine, beer and spirits were assessed; gender-specific food factors were identified by factor analyses. Multiple linear regression analyses were done before and after adjustment for concurrent changes in BMI. A high intake of potatoes seemed to prevent gain in WC for men, while a high intake of refined bread was associated with gain in WC for women. The association persisted for refined bread, but not for potatoes, after adjustment for concurrent BMI changes. Among women, but not men, high intakes of beer and spirits were associated with gain in WC in both models. A high intake of coffee for women and moderate to high intake of tea for men were associated with gain in WC, but the associations were weakened, especially for women, after adjustment for BMI changes. None of the food factors was associated with WC changes. Based on the present study, we conclude that very few food items and no food patterns seem to predict changes in WC, whereas high intakes of beer and spirits among women, and moderate to high tea intake among men, may promote gain in WC.
C1 Copenhagen Univ Hosp, Danish Epidemiol Sci Ctr, Inst Prevent Med, Copenhagen, Denmark.
   Copenhagen Univ Hosp, Res Unit Dietary Studies, Inst Prevent Med, Copenhagen, Denmark.
   Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark.
   Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark.
C3 University of Copenhagen; Copenhagen University Hospital; Aarhus University; University of Copenhagen; Copenhagen University Hospital; University of Copenhagen; Copenhagen University Hospital; Danish Cancer Society
RP Copenhagen Univ Hosp, Danish Epidemiol Sci Ctr, Inst Prevent Med, Copenhagen, Denmark.
EM jh@ipm.hosp.dk
CR BAECKE JAH, 1983, INT J OBESITY, V7, P13
   Bigaard J, 2003, OBES RES, V11, P895, DOI 10.1038/oby.2003.123
   Bjorntorp P, 1996, INT J OBESITY, V20, P291
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   Brand-Miller JC, 2002, AM J CLIN NUTR, V76, P281S, DOI 10.1093/ajcn/76.1.281S
   Carey DGP, 1996, INT J OBESITY, V20, P722
   Chan DC, 2003, QJM-INT J MED, V96, P441, DOI 10.1093/qjmed/hcg069
   CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961
   COLDITZ GA, 1990, AM J CLIN NUTR, V51, P1100, DOI 10.1093/ajcn/51.6.1100
   Dallongeville J, 1998, INT J OBESITY, V22, P1178, DOI 10.1038/sj/ijo/0800744
   Delvaux K, 1999, INT J OBESITY, V23, P1233, DOI 10.1038/sj.ijo.0801052
   Dobbelsteyn CJ, 2001, INT J OBESITY, V25, P652, DOI 10.1038/sj.ijo.0801582
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   DUNCAN BB, 1995, AM J EPIDEMIOL, V142, P1034, DOI 10.1093/oxfordjournals.aje.a117556
   Ebbeling C B, 2001, ADV PEDIATR, V48, P179
   ECK LH, 1995, INT J OBESITY, V19, P765
   Fung TT, 2001, AM J CLIN NUTR, V73, P61
   GEORGE V, 1990, INT J OBESITY, V14, P1085
   Greenwood DC, 2000, EUR J CLIN NUTR, V54, P314, DOI 10.1038/sj.ejcn.1600941
   GRINKER JA, 1995, OBES RES, V3, P435, DOI 10.1002/j.1550-8528.1995.tb00173.x
   Han TS, 1998, INT J EPIDEMIOL, V27, P422, DOI 10.1093/ije/27.3.422
   Haveman-Nies A, 2001, EUR J CLIN NUTR, V55, P870, DOI 10.1038/sj.ejcn.1601232
   Heitmann BL, 2000, INT J OBESITY, V24, P435, DOI 10.1038/sj.ijo.0801176
   HEITMANN BL, 1995, BRIT MED J, V311, P986
   Hu FB, 2000, AM J CLIN NUTR, V72, P912
   Jacobs DR, 1998, AM J CLIN NUTR, V68, P248, DOI 10.1093/ajcn/68.2.248
   JACOBSEN BK, 1987, J CHRON DIS, V40, P795, DOI 10.1016/0021-9681(87)90131-7
   Johansen D, 2003, ALCOHOL, V31, P11, DOI 10.1016/j.alcohol.2003.04.001
   Kahn HS, 1997, AM J PUBLIC HEALTH, V87, P747, DOI 10.2105/AJPH.87.5.747
   Kamycheva E, 2003, J NUTR, V133, P102, DOI 10.1093/jn/133.1.102
   KAYE SA, 1990, INT J OBESITY, V14, P583
   Koh-Banerjee P, 2003, AM J CLIN NUTR, V78, P719, DOI 10.1093/ajcn/78.4.719
   KROMHOUT D, 1988, AM J CLIN NUTR, V47, P668, DOI 10.1093/ajcn/47.4.668
   Lakka HM, 2002, EUR HEART J, V23, P706, DOI 10.1053/euhj.2001.2889
   LAPIDUS L, 1989, APPETITE, V13, P25, DOI 10.1016/0195-6663(89)90024-X
   Larson DE, 1996, AM J CLIN NUTR, V64, P677, DOI 10.1093/ajcn/64.5.677
   LAWS A, 1990, AM J PUBLIC HEALTH, V80, P1358, DOI 10.2105/AJPH.80.11.1358
   LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158
   Lemieux S, 1997, INT J OBESITY, V21, P831, DOI 10.1038/sj.ijo.0800488
   Liebman M, 2003, INT J OBESITY, V27, P684, DOI 10.1038/sj.ijo.0802277
   Lissner L, 2001, OBES RES, V9, P644, DOI 10.1038/oby.2001.85
   Lissner L, 2000, BRIT J NUTR, V83, P0
   Ludwig DS, 2000, J NUTR, V130, P280S, DOI 10.1093/jn/130.2.280S
   Ludwig DS, 1999, JAMA-J AM MED ASSOC, V282, P1539, DOI 10.1001/jama.282.16.1539
   McKeown NM, 2002, AM J CLIN NUTR, V76, P390, DOI 10.1093/ajcn/76.2.390
   MERKUS MP, 1995, J EPIDEMIOL COMMUN H, V49, P22, DOI 10.1136/jech.49.1.22
   Meyer KA, 2000, AM J CLIN NUTR, V71, P921
   Morris KL, 1999, NUTR REV, V57, P273
   Nelson TL, 1999, INT J OBESITY, V23, P449, DOI 10.1038/sj.ijo.0800840
   Newby P, 2003, AM J CLIN NUTR, V77, P1417, DOI 10.1093/ajcn/77.6.1417
   Osler M, 1996, INT J EPIDEMIOL, V25, P1023, DOI 10.1093/ije/25.5.1023
   Osler M, 2002, EUR J CLIN NUTR, V56, P568, DOI 10.1038/sj.ejcn.1601360
   Osler M, 2001, BRIT J NUTR, V85, P219, DOI 10.1079/BJN2000240
   Rexrode KM, 1998, JAMA-J AM MED ASSOC, V280, P1843, DOI 10.1001/jama.280.21.1843
   Rexrode KM, 2001, INT J OBESITY, V25, P1047, DOI 10.1038/sj.ijo.0801615
   Rosell MS, 2003, AM J CLIN NUTR, V78, P84, DOI 10.1093/ajcn/78.1.84
   Sakurai Y, 1997, EUR J EPIDEMIOL, V13, P893, DOI 10.1023/A:1007416322031
   Singh RB, 1996, J AM COLL NUTR, V15, P592, DOI 10.1080/07315724.1996.10718635
   SLATTERY ML, 1992, AM J CLIN NUTR, V55, P943, DOI 10.1093/ajcn/55.5.943
   Stookey JD, 2001, J NUTR, V131, P2433S, DOI 10.1093/jn/131.9.2433S
   TAVANI A, 1994, INT J OBESITY, V18, P497
   Toeller M, 2001, INT J OBESITY, V25, P1815, DOI 10.1038/sj.ijo.0801816
   Togo P, 2004, INT J OBESITY, V28, P583, DOI 10.1038/sj.ijo.0802598
   Togo P, 2003, BRIT J NUTR, V90, P667, DOI 10.1079/BJN2003943
   Trichopoulou A, 2001, AM J CLIN NUTR, V74, P574
   TROISI RJ, 1991, AM J CLIN NUTR, V53, P1104, DOI 10.1093/ajcn/53.5.1104
   TUCKER KL, 1992, J AM DIET ASSOC, V92, P1487
   Vadstrup ES, 2003, INT J OBESITY, V27, P238, DOI 10.1038/sj.ijo.802203
   van Lenthe FJ, 1998, AM J CLIN NUTR, V67, P846, DOI 10.1093/ajcn/67.5.846
   Van Pelt RE, 2002, AM J PHYSIOL-ENDOC M, V282, PE1023, DOI 10.1152/ajpendo.00467.2001
   Walker SP, 1996, AM J EPIDEMIOL, V144, P1143, DOI 10.1093/oxfordjournals.aje.a008892
   Wannamethee SG, 2003, AM J CLIN NUTR, V77, P1312, DOI 10.1093/ajcn/77.5.1312
   Willett WC, 1998, NUTR EPIDEMIOLOGY, V0, P0
   Williams DEM, 2000, BRIT J NUTR, V83, P257, DOI 10.1017/S0007114500000337
   WILLIAMSON DF, 1987, AM J PUBLIC HEALTH, V77, P1324, DOI 10.2105/AJPH.77.10.1324
   Wirfalt AKE, 1997, J AM DIET ASSOC, V97, P272, DOI 10.1016/S0002-8223(97)00071-0
   Wirfält E, 2001, AM J EPIDEMIOL, V154, P1150, DOI 10.1093/aje/154.12.1150
   Yoshioka M, 2001, BRIT J NUTR, V85, P203, DOI 10.1079/BJN2000224
NR 78
TC 73
Z9 81
U1 0
U2 15
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD OCT 15
PY 2004
VL 92
IS 4
BP 735
EP 748
DI 10.1079/BJN20041246
PG 14
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 864NJ
UT WOS:000224639900021
PM 15522143
DA 2025-04-28
ER

PT J
AU Persky, AM
   Ng, C
   Song, MH
   Lancaster, ME
   Balderson, DE
   Paulik, MA
   Brouwer, KLR
AF Persky, AM
   Ng, C
   Song, MH
   Lancaster, ME
   Balderson, DE
   Paulik, MA
   Brouwer, KLR
TI Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE weight loss; infrared thermography; therapeutic index
ID energy-expenditure; weight-loss; adipose-tissue; women; caffeine; obese
AB Objective: With an increase in the incidence of obesity, tremendous effort has been devoted to the development of weight loss agents and the prospective surrogate markers of both a product's efficacy and safety. The objective of the present study was to compare the pharmacodynamic responses of ephedrine and sibutramine using surrogate markers of weight loss potential and potential adverse events. Design and subjects: The study was designed as a 5-way, randomized, double-blinded, placebo-controlled trial with 3 single doses of ephedrine sulfate (0.25, 0.5 and 1 mg x kg(-1)) followed by an open-labeled sibutramine (10 mg) treatment. Healthy, mildly overweight (BMI = 25) subjects were administered the respective treatment and pharmacokinetic and pharmacodynamic measurements (body surface temperature, resting metabolic rate, blood pressure, heart rate, glucose, glycerol, nonesterified fatty acids, triglycerides) were obtained for 8 hours post dose and for an additional 4 measurements during the sibutramine treatment period. Results: Sibutramine treatment significantly increased resting metabolic rate compared to the placebo condition. Ephedrine significantly increased heart rate, systolic blood pressure and glucose but did not significantly affect other measurements. Conclusion: Both sibutramine and ephedrine have been shown to have weight loss potential, however, they elicit different metabolic and biochemical responses after a single dose. The nontherapeutic responses from these types of compounds may serve as a screening tool for the development of agents in the treatment of obesity.
C1 Univ N Carolina, Div Drug Delivery & Disposit, Sch Pharm, Chapel Hill, NC 27599 USA.
   GlaxoSmithKline, Res Triangle Pk, NC USA.
C3 University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline; Glaxosmithkline USA
RP Univ N Carolina, Div Drug Delivery & Disposit, Sch Pharm, Kerr Hall,CB 7360, Chapel Hill, NC 27599 USA.
FU NCRR NIH HHS [RR00046] Funding Source: Medline
CR Unknown -, 2000, WHO TECHN REP SER, V0, P0
   ASTRUP A, 1991, METABOLISM, V40, P323, DOI 10.1016/0026-0495(91)90117-F
   ASTRUP A, 1992, METABOLISM, V41, P686, DOI 10.1016/0026-0495(92)90304-S
   ASTRUP A, 1993, INT J OBESITY, V17, P0
   Berlin I, 2001, EUR J CLIN PHARMACOL, V57, P447, DOI 10.1007/s002280100317
   Doucet E, 2000, J CLIN ENDOCR METAB, V85, P4231, DOI 10.1210/jc.85.11.4231
   Doucet E, 2002, EUR J CLIN NUTR, V56, P297, DOI 10.1038/sj.ejcn.1601334
   Farrigan C, 2002, NAT REV DRUG DISCOV, V1, P257, DOI 10.1038/nrd781
   Haller CA, 2002, CLIN PHARMACOL THER, V71, P421, DOI 10.1067/mcp.2002.124523
   Hansen DL, 1998, AM J CLIN NUTR, V68, P1180, DOI 10.1093/ajcn/68.6.1180
   Hansen DL, 1999, INT J OBESITY, V23, P1016, DOI 10.1038/sj.ijo.0801059
   HORTON TJ, 1991, INT J OBESITY, V15, P359
   Krejs QJ, 2002, INT J OBESITY, V26, PS34, DOI 10.1038/sj.ijo.0802217
   Narkiewicz K, 2002, INT J OBESITY, V26, PS38, DOI 10.1038/sj.ijo.0802218
   NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0
   Persky AM, 2004, BRIT J CLIN PHARMACO, V57, P552, DOI 10.1111/j.1365-2125.2003.02062.x
   Satomura S, 2001, METABOLISM, V50, P1181, DOI 10.1053/meta.2001.26701
   Schiffelers SLH, 2001, INT J OBESITY, V25, P33, DOI 10.1038/sj.ijo.0801528
   Seagle HM, 1998, OBES RES, V6, P115, DOI 10.1002/j.1550-8528.1998.tb00324.x
   Shannon JR, 1999, CLIN SCI, V96, P483, DOI 10.1042/CS19980206
   Sharma AM, 2001, INT J OBESITY, V25, PS20, DOI 10.1038/sj.ijo.0801934
   Starling RD, 2001, OBES RES, V9, P251, DOI 10.1038/oby.2001.29
NR 22
TC 5
Z9 6
U1 0
U2 6
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0946-1965
EI 
J9 INT J CLIN PHARM TH
JI Int. J. Clin. Pharmacol. Ther.
PD AUG 15
PY 2004
VL 42
IS 8
BP 442
EP 448
DI 
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 842UO
UT WOS:000223030000004
PM 15366324
DA 2025-04-28
ER

PT J
AU White, AA
   Nitzke, S
   Peterson, KE
AF White, AA
   Nitzke, S
   Peterson, KE
TI Are soft drinks getting a burn rap? We don't think so
SO JOURNAL OF NUTRITION EDUCATION AND BEHAVIOR
LA English
DT Article
DE carbonated beverages; schools; nutrition; policy
ID dental-cary; beverage consumption; caffeine withdrawal; children; adolescents; patterns; obesity; sugars; girls; foods
AB The viewpoint presented in this article is that soft drink consumption is a contributing factor in the rising incidence of overweight among school-aged children. Misinformation must be dispelled so that resources can be directed to real, evidence-based concerns. Child nutrition advocates have called for reducing access to soft drinks in schools as an important step in optimizing healthful environments for children. School nutrition policies are being revised at national, state, and local levels. Along with other stakeholders, soft drink manufacturers must acknowledge the problem of rising rates of overweight in children and work within their spheres of influence to limit access to soft drinks in schools.
C1 Univ Maine, Dept Food Sci & Human Nutr, Orono, ME 04469 USA.
   Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA.
   Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
C3 University of Maine System; University of Maine Orono; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health
RP Univ Maine, Dept Food Sci & Human Nutr, 5735 Hitchner Hall, Orono, ME 04469 USA.
EM aawhite@umenfa.maine.edu
CR *AM PUBL HLTH ASS, 2003, POL STAT 2003 17 FOO, V0, P0
   Unknown -, 2004, J AM DIET ASSOC, V104, P660, DOI 10.1016/j.jada.2004.01.030
   Unknown -, 2000, MEMORANDUM, V0, P0
   Berg F, 2003, J NUTR EDUC BEHAV, V35, P1
   BOWMAN DH, 2003, ED WEEK 1003, V0, P0
   Briggs M, 2003, J NUTR EDUC BEHAV, V35, P57, DOI 10.1016/S1499-4046(06)60040-7
   *CAL PROJ LEAN PUB, 2002, TAK FIZZ OUT SOD CON, V0, P0
   DAY S, 2004, NY TIMES 0903, V0, P0
   Erickson Pamela R, 1998, PEDIATRIC DENTISTRY, V20, P395
   Evans SM, 1999, J PHARMACOL EXP THER, V289, P285
   Fisher JO, 2001, J NUTR, V131, P246, DOI 10.1093/jn/131.2.246
   Fitzpatrick L, 2003, J BONE MINER RES, V18, P1570, DOI 10.1359/jbmr.2003.18.9.1570
   French SA, 2003, J AM DIET ASSOC, V103, P1326, DOI 10.1016/S0002-8223(03)01076-9
   Gibson S, 1999, CARIES RES, V33, P101, DOI 10.1159/000016503
   Gleason P, 2001, DIETARY INTAKE ITS R, V0, P0
   GRIFFITHS RR, 1989, J EXP ANAL BEHAV, V52, P127, DOI 10.1901/jeab.1989.52-127
   Guthrie JF, 2000, J AM DIET ASSOC, V100, P43, DOI 10.1016/S0002-8223(00)00018-3
   Harnack L, 1999, J AM DIET ASSOC, V99, P436, DOI 10.1016/S0002-8223(99)00106-6
   Heaney RP, 2001, AM J CLIN NUTR, V74, P343
   Heller KE, 2001, J DENT RES, V80, P1949, DOI 10.1177/00220345010800101701
   Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857
   *INT FOOD INF COUN, 1998, EV YOU NEED KNOW CAF, V0, P0
   ISMAIL AI, 1984, J AM DENT ASSOC, V109, P241, DOI 10.14219/jada.archive.1984.0346
   James J, 2004, BMJ-BRIT MED J, V328, P1237, DOI 10.1136/bmj.38077.458438.EE
   James JE, 1991, CAFFEINE HLTH, V0, P0
   Jones HE, 2000, PSYCHOPHARMACOLOGY, V147, P371, DOI 10.1007/s002130050005
   KLEEMOLAKUJALA E, 1979, COMMUNITY DENT ORAL, V7, P199, DOI 10.1111/j.1600-0528.1979.tb01216.x
   Krebs NF, 2003, PEDIATRICS, V112, P424, DOI 10.1542/peds.112.2.424
   Krebs-Smith SM, 2001, J NUTR, V131, P527S, DOI 10.1093/jn/131.2.527S
   *LIF SCI RES OFF, 1989, DHHS PUB PHS, V0, P0
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   Lytle LA, 2000, AM J HEALTH PROMOT, V14, P222, DOI 10.4278/0890-1171-14.4.222
   MARR L, 2004, J NUTR ED BEHAV, V36, P0
   Marshall TA, 2003, PEDIATRICS, V112, PE184, DOI 10.1542/peds.112.3.e184
   Mattes Richard D, 1996, PHYSIOLOGY AND BEHAVIOR, V59, P179, DOI 10.1016/0031-9384(95)02007-1
   McNeal James, 1999, THE KIDS MARKET: MYTHS AND REALITIES, V0, P0
   Mor B M, 1983, N Z DENT J, V79, P10
   Mrdjenovic G, 2003, J PEDIATR-US, V142, P604, DOI 10.1067/mpd.2003.200
   MUMFORD GK, 1994, PSYCHOPHARMACOLOGY, V115, P1, DOI 10.1007/BF02244744
   *NAT SOFT DRINK AS, 2003, STAT RESP AAP REL SO, V0, P0
   NESTLE M, 2002, FOOD POLITICS, V0, P175
   NESTLE M, 2002, FOOD POLITICS, V0, P197
   Skinner JD, 2003, J AM DIET ASSOC, V103, P1626, DOI 10.1016/j.jada.2003.09.018
   Sloan AE, 2003, FOOD TECHNOL-CHICAGO, V57, P20
   Smit HJ, 2000, PSYCHOPHARMACOLOGY, V152, P167, DOI 10.1007/s002130000506
   SPRAYCAR M, 1995, STEDMANS MED DICT, V0, P0
   St-Onge MP, 2003, AM J CLIN NUTR, V78, P1068, DOI 10.1093/ajcn/78.6.1068
   Stitzel K, 2003, J AM DIET ASSOC, V103, P439, DOI 10.1053/jada.2003.50102
   STUHLDREHER WL, 1998, J CHILD NUTR MANAGE, V22, P79
   Taras HL, 2004, PEDIATRICS, V113, P152
   *TX I HLTH POL RES, 2001, NUTR FITN TEX SCH PO, V0, P0
   *US CDCP SHPPS, 2000, SCH HLTH POL PROGR S, V0, P0
   *USDA, 1983, H6 USDA HUM NUTR INF, V0, P0
   *USDA, 2000, SPEC NOT DAT US US D, V0, P0
   *USDA, 1984, 1 USDA HUM NUTR INF, V0, P0
   *USDA USDEPHHS PHS, 2000, NUTR YOUR HLTH DIET, V232, P0
   Vail K, 1999, AMERICAN SCHOOL BOARD JOURNAL, V0, P0
   *W VA DEP ED, 2002, EX SUMM STAND SCH NU, V0, P0
   Wyshak G, 2000, ARCH PEDIAT ADOL MED, V154, P610, DOI 10.1001/archpedi.154.6.610
NR 65
TC 5
Z9 5
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1499-4046
EI 1878-2620
J9 J NUTR EDUC BEHAV
JI J. Nutr. Educ. Behav.
PD SEP-OCT 15
PY 2004
VL 36
IS 5
BP 266
EP 271
DI 10.1016/S1499-4046(06)60390-4
PG 6
WC Education, Scientific Disciplines; Nutrition & Dietetics
SC Education & Educational Research; Nutrition & Dietetics
GA 877WD
UT WOS:000225604300011
PM 15707550
DA 2025-04-28
ER

PT J
AU Zampelas, A
   Panagiotakos, DB
   Pitsavos, C
   Chrysohoou, C
   Stefanadis, C
AF Zampelas, A
   Panagiotakos, DB
   Pitsavos, C
   Chrysohoou, C
   Stefanadis, C
TI Associations between coffee consumption and inflammatory markers in healthy persons: the ATTICA study
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE inflammation; cardiovascular disease; risk factors; coffee
ID caffeine; protein; cafestol; obesity; disease; lipids
AB Background: The effect of coffee consumption on the cardiovascular system is conflicting. Inflammation is important to the development of cardiovascular disease (CVD), and several dietary factors are thought to exert significant effects on inflammation and thus on the risk of CVD. Objective: We aimed to investigate the associations between coffee consumption and inflammatory markers. Design: The cross-sectional survey enrolled 1514 men ((x) over bar +/- SD age: 46 +/- 13 y; range: 18-87 y) and 1528 women (aged 45 +/- 13 y; range: 18-89 y). Five percent of men and 3% of women were excluded for history of CVD. Fasting blood samples were collected. Dietary habits (including consumption of various types of coffee) were evaluated by using a validated food-frequency questionnaire. Results: Compared with coffee nondrinkers, men who consumed >200 mL coffee/d had 50% higher interleukin 6 (IL-6), 30% higher C-reactive protein (CRP), 12% higher serum amyloid-A (SAA), and 28% higher tumor necrosis factor alpha (TNF-alpha) concentrations and 3% higher white blood cell (WBC) counts (all: P < 0.05). Women who consumed >200 mL coffee/d had 54% higher IL-6, 38% higher CRP, 28% higher SAA, and 28% higher TNF-alpha concentrations and 4% higher WBC counts (all: P < 0.05) than did coffee nondrinkers. The findings were significant even after control for the interactions between coffee consumption and age, sex, smoking, body mass index, physical activity status, and other covariates. Conclusions: A relation exists between moderate-to-high coffee consumption and increased inflammation process. This relation could explain, in part, the effect of increased coffee intake on the cardiovascular system.
C1 Harokopio Univ, Dept Nutr & Dietet, Athens, Greece.
   Univ Athens, Sch Med, Cardiol Clin 1, GR-11527 Athens, Greece.
C3 Harokopio University Athens; National & Kapodistrian University of Athens; Athens Medical School
RP 46 Paleon Polemiston St, Attica 16674, Greece.
EM d.b.panagiotakos@usa.net
CR BATTIG K, 1992, SCHWEIZ MED WSCHR, V122, P1536
   BAUMANN H, 1990, MOL BIOL MED, V7, P147
   BUNKER ML, 1979, J AM DIET ASSOC, V74, P28
   CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4
   Das UN, 2002, EXP BIOL MED, V227, P989, DOI 10.1177/153537020222701106
   Das UN, 2002, NUTRITION, V18, P430, DOI 10.1016/S0899-9007(01)00747-X
   Das UN, 2002, PROSTAG LEUKOTR ESS, V67, P1, DOI 10.1054/plef.2002.0374
   Das UN, 2001, NUTRITION, V17, P953, DOI 10.1016/S0899-9007(01)00672-4
   GANAPATHI MK, 1990, BIOCHEM J, V269, P41, DOI 10.1042/bj2690041
   GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504
   Grubben MJ, 2000, AM J CLIN NUTR, V71, P480
   GYNTELBERG F, 1995, J INTERN MED, V237, P55, DOI 10.1111/j.1365-2796.1995.tb01140.x
   Katsouyanni K, 1997, INT J EPIDEMIOL, V26, PS118, DOI 10.1093/ije/26.suppl_1.S118
   KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480
   Klag Michael J, 1994, ANNALS OF EPIDEMIOLOGY, V4, P425, DOI 10.1016/1047-2797(94)90001-9
   Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705
   Nawrot P, 2003, FOOD ADDIT CONTAM A, V20, P1, DOI 10.1080/0265203021000007840
   PALMER JR, 1995, AM J EPIDEMIOL, V141, P724, DOI 10.1093/oxfordjournals.aje.a117494
   Panagiotakos DB, 2003, J NUTR, V133, P3228, DOI 10.1093/jn/133.10.3228
   Piek JJ, 2000, J AM COLL CARDIOL, V35, P963, DOI 10.1016/S0735-1097(99)00647-6
   Pitsavos C, 2003, BMC PUBLIC HEALTH, V3, P0, DOI 10.1186/1471-2458-3-32
   Rustan AC, 1997, ARTERIOSCL THROM VAS, V17, P2140, DOI 10.1161/01.ATV.17.10.2140
   Sakamoto W, 2001, BONE, V28, P332, DOI 10.1016/S8756-3282(00)00444-0
   Simopoulos AP, 2002, J AM COLL NUTR, V21, P495, DOI 10.1080/07315724.2002.10719248
   Terpstra AHM, 2000, J NUTR BIOCHEM, V11, P311, DOI 10.1016/S0955-2863(00)00082-6
   Thelle Dag S, 1995, CURRENT OPINION IN LIPIDOLOGY, V6, P25, DOI 10.1097/00041433-199502000-00006
   World Health Organization, 1990, WORLD HEALTH ORGAN TECH REP SER, V797, P1
   Yamada T, 1999, CLIN CHEM LAB MED, V37, P381, DOI 10.1515/CCLM.1999.063
NR 28
TC 140
Z9 153
U1 0
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT 15
PY 2004
VL 80
IS 4
BP 862
EP 867
DI 10.1093/ajcn/80.4.862
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 856VI
UT WOS:000224073000010
PM 15447891
DA 2025-04-28
ER

PT J
AU Kovacs, EMR
   Lejeune, MPGM
   Nijs, I
   Westerterp-Plantenga, MS
AF Kovacs, EMR
   Lejeune, MPGM
   Nijs, I
   Westerterp-Plantenga, MS
TI Effects of green tea on weight maintenance after body-weight loss
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE epigallocatechin gallate; energy expenditure; substrate oxidation; obesity
ID respiration chamber; fat oxidation; follow-up; obesity; women; diet; supplementation; carbohydrate; inhibition; caffeine
AB The present study was conducted to investigate whether green tea may improve weight maintenance by preventing or limiting weight regain after weight loss of 5 to 10 % in overweight and moderately obese subjects. The study had a randomised, parallel, placebo-controlled design. A total of 104 overweight and moderately obese male and female subjects (age 18-60 years; BMI 25-35 kg/m(2)) participated. The study consisted of a very-low-energy diet intervention (VLED; 2.1 MJ/d) of 4 weeks followed by a weight-maintenance period of 13 weeks in which the subjects received green tea or placebo. The green tea contained caffeine (104 mg/d) and catechins (573 mg/d, of which 323 mg was epigallocatechin gallate). Subjects lost 6.4 (SD 1.9) kg or 7.5 (SD 2.2) % of their original body weight during the VLED (P<0.001). Body-weight regain was not significantly different between the green tea and the placebo group (30.5 (SD 61.8) % and 19.7 (SD 56.9) %, respectively). In the green tea treatment, habitual high caffeine consumption was associated with a higher weight regain compared with habitual low caffeine consumption (39 (SD 17) and 16 (SD 11) %, respectively; P<0.05). We conclude that weight maintenance after 7.5 % body-weight loss was not affected by green tea treatment and that habitual caffeine consumption affected weight maintenance in the green tea treatment.
C1 Maastricht Univ, Dept Human Biol, Maastricht, Netherlands.
C3 Maastricht University
RP Maastricht Univ, Dept Human Biol, Maastricht, Netherlands.
EM M.Westerterp@HB.UNIMAAS.NL
CR BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   Ekelund U, 2000, INT J SPORTS MED, V21, P586, DOI 10.1055/s-2000-8487
   GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397
   Goris AHC, 2001, AM J CLIN NUTR, V73, P549
   Herman CP, 1980, OBESITY, V0, P208
   KRAMER FM, 1989, INT J OBESITY, V13, P123
   LICHTENBELT WDV, 1994, BRIT J NUTR, V72, P491, DOI 10.1079/BJN19940053
   Pasman WJ, 1997, INT J OBESITY, V21, P1143, DOI 10.1038/sj.ijo.0800528
   Pasman WJ, 1997, INT J OBESITY, V21, P548, DOI 10.1038/sj.ijo.0800439
   Pasman WJ, 1999, METABOLISM, V48, P15, DOI 10.1016/S0026-0495(99)90004-5
   PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   SCHOELLER DA, 1980, AM J CLIN NUTR, V33, P2686, DOI 10.1093/ajcn/33.12.2686
   Schoffelen PFM, 1997, J APPL PHYSIOL, V83, P2064, DOI 10.1152/jappl.1997.83.6.2064
   SEIDELL JC, 1995, OBES RES S2, V3, P0
   STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8
   VanGaal LF, 1997, INT J OBESITY, V21, P0
   WADDEN TA, 1988, J CONSULT CLIN PSYCH, V56, P925, DOI 10.1037/0022-006X.56.6.925
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363
   Westerterp KR, 2001, NATURE, V410, P539, DOI 10.1038/35069142
   Westerterp-Plantenga MS, 1998, INT J OBESITY, V22, P1, DOI 10.1038/sj.ijo.0800536
   Westerterp-Plantenga MS, 2001, BRIT J NUTR, V85, P351, DOI 10.1079/BJN2000272
   Westerterp-Plantenga MS, 1999, EUR J CLIN NUTR, V53, P495, DOI 10.1038/sj.ejcn.1600782
NR 25
TC 177
Z9 197
U1 2
U2 46
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD MAR 15
PY 2004
VL 91
IS 3
BP 431
EP 437
DI 10.1079/BJN20041061
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 808ZV
UT WOS:000220607900014
PM 15005829
DA 2025-04-28
ER

PT J
AU Robinson, LE
   Savani, S
   Battram, DS
   McLaren, DH
   Sathasivam, P
   Graham, TE
AF Robinson, LE
   Savani, S
   Battram, DS
   McLaren, DH
   Sathasivam, P
   Graham, TE
TI Caffeine ingestion before an oral glucose tolerance test impairs blood glucose management in men with type 2 diabetes
SO JOURNAL OF NUTRITION
LA English
DT Article; Proceedings Paper
DE caffeine; carbohydrate; insulin resistance; hyperinsulinemia; insulin sensitivity index
ID coffee consumption; insulin sensitivity; life-style; risk; mellitus; resistance
AB Caffeine ingestion negatively affects insulin sensitivity during an oral glucose tolerance test (OGTT) in lean and obese men, but this has not been studied in individuals with type 2 diabetes. We examined the effects of caffeine ingestion on insulin and glucose homeostasis in obese men with type 2 diabetes. Men (n = 12) with type 2 diabetes (age = 49 +/- 2 y, BMI = 32 +/- 1 kg/m(2)) underwent 2 trials, 1 wk apart, in a randomized, double-blind design. Each trial was conducted after withdrawal from caffeine, alcohol, exercise, and oral hypoglycemic agents for 48 h and an overnight fast. Subjects randomly ingested caffeine (5 mg/kg body weight) or placebo capsules and 1 h later began a 3 h 75 g OGTT. Caffeine increased (P < 0.05) serum insulin, proinsulin, and C-peptide concentrations during the OGTT relative to placebo. Insulin area under the curve was 25% greater (P < 0.05) after caffeine than after placebo ingestion. Despite this, blood glucose concentration was also increased (P < 0.01) in the caffeine trial. After caffeine ingestion, blood glucose remained elevated (P < 0.01) at 3 h postglucose load (8.9 +/- 0.7 mmol/L) compared with baseline (6.7 +/- 0.4 mmol/L). The insulin sensitivity index was lower (14%, P = 0.02) after caffeine than after placebo ingestion. Overall, despite elevated and prolonged proinsulin, C-peptide, and insulin responses after caffeine ingestion, blood glucose was also increased, suggesting an acute caffeine-induced impairment in blood glucose management in men with type 2 diabetes.
C1 Univ Guelph, Dept Human Biol & Nutrit Sci, Guelph, ON N1G 2W1, Canada.
C3 University of Guelph
RP Univ Guelph, Dept Human Biol & Nutrit Sci, Guelph, ON N1G 2W1, Canada.
EM Lrobinso@uoguelph.ca
CR Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   ALLISON DB, 1995, DIABETES CARE, V18, P245, DOI 10.2337/diacare.18.2.245
   Amos A F, 1997, DIABET MED, V14 Suppl 5, P0
   ARNAUD NJ, 1993, CAFFEINE COFFEE HLTH, V0, P43
   Azam Sonish, 2003, MED SCI MONIT, V9, P0
   Barone JJ, 1996, FOOD CHEM TOXICOL, V34, P119, DOI 10.1016/0278-6915(95)00093-3
   BATTRAM D, 2000, 43 ANN M CAN FED BIO, V0, P0
   Bruton JD, 2002, FASEB J, V16, P301, DOI 10.1096/fj.02-0481fje
   Carlsson S, 2004, INT J EPIDEMIOL, V33, P616, DOI 10.1093/ije/dyh185
   de Galan BE, 2002, DIABETES, V51, P790, DOI 10.2337/diabetes.51.3.790
   Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1
   Fritsche A, 2002, DIABETES, V51, PS234, DOI 10.2337/diabetes.51.2007.S234
   Graham TE, 2001, CAN J PHYSIOL PHARM, V79, P559, DOI 10.1139/cjpp-79-7-559
   Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349
   Haffner SM, 2003, AM J CARDIOL, V92, P18J, DOI 10.1016/S0002-9149(03)00612-X
   Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   LOWRY OH, 1993, ENZYMATIC ANAL PRACT, V0, P171
   Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462
   McCarthy Mark I, 2003, CURR DIAB REP, V3, P159, DOI 10.1007/s11892-003-0040-y
   Natella F, 2002, J AGR FOOD CHEM, V50, P6211, DOI 10.1021/jf025768c
   Nawrot P, 2003, FOOD ADDIT CONTAM A, V20, P1, DOI 10.1080/0265203021000007840
   Panagiotakos DB, 2003, J NUTR, V133, P3228, DOI 10.1093/jn/133.10.3228
   Petrie HJ, 2004, AM J CLIN NUTR, V80, P22
   Pi-Sunyer FX, 1998, OBES RES, V6, P0
   Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Saremi A, 2003, DIABETES CARE, V26, P2211, DOI 10.2337/diacare.26.7.2211
   Shearer J, 2003, J NUTR, V133, P3529, DOI 10.1093/jn/133.11.3529
   Spiller MA, 1998, CAFFEINE, V0, P97
   Thong FSL, 2002, J APPL PHYSIOL, V92, P2347, DOI 10.1152/japplphysiol.01229.2001
   Thong FSL, 2002, DIABETES, V51, P583, DOI 10.2337/diabetes.51.3.583
   Tominaga M, 1999, DIABETES CARE, V22, P920, DOI 10.2337/diacare.22.6.920
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
NR 37
TC 76
Z9 89
U1 0
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD OCT 15
PY 2004
VL 134
IS 10
BP 2528
EP 2533
DI 10.1093/jn/134.10.2528
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 859SN
UT WOS:000224288300006
PM 15465742
DA 2025-04-28
ER

PT J
AU Tuomilehto, J
   Hu, G
   Bidel, S
   Lindström, J
   Jousilahti, P
AF Tuomilehto, J
   Hu, G
   Bidel, S
   Lindström, J
   Jousilahti, P
TI Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID gastric-inhibitory polypeptide; insulin-resistance; glucose-tolerance; physical-activity; chlorogenic acid; caffeine intake; leisure-time; life-style; green tea; disease
AB Context Only a few studies of coffee consumption and diabetes mellitus (DM) have been reported, even though coffee is the most consumed beverage in the world. Objective To determine the relationship between coffee consumption and the incidence of type 2 DM among Finnish individuals, who have the highest coffee consumption in the world. Design, Setting, and Participants A prospective study from combined surveys conducted in 1982, 1987, and 1992 of 6974 Finnish men and 7655 women aged 35 to 64 years without history of stroke, coronary heart disease, or DM at baseline, with 175682 person-years of follow-up. Coffee consumption and other study parameters were determined at baseline using standardized measurements. Main Outcome Measures Hazard ratios (HRs) for the incidence of type 2 DM were estimated for different levels of daily coffee consumption. Results During a mean follow-up of 12 years, there were 381 incident cases of type 2 DM. After adjustment for confounding factors (age, study year, body mass index, systolic blood pressure, education, occupational, commuting and leisure-time physical activity, alcohol and tea consumption, and smoking), the HRs of DM associated with the amount of coffee consumed daily (0-2, 3-4, 5-6, 7-9, greater than or equal to10 cups) were 1.00, 0.71 (95% confidence interval [CI], 0.48-1.05), 0.39 (95% CI, 0.25-0.60), 0.39 (95% CI, 0.20-0.74), and 0.21 (95% CI, 0.06-0.69) (P for trend <.001) in women, and 1.00, 0.73 (95% CI, 0.47-1.13), 0.70 (95% CI, 0.45-1.05), 0.67 (95% CI, 0.40-1.12), and 0.45 (95% CI, 0.25-0.81) (P for trend=.12) in men, respectively. In both sexes combined, the multivariate-adjusted inverse association was significant (P for trend <.001) and persisted when stratified by younger and older than 50 years; smokers and never smokers; healthy weight, overweight, and obese participants; alcohol drinker and nondrinker; and participants drinking filtered and nonfiltered coffee. Conclusion Coffee drinking has a graded inverse association with the risk of type 2 DM; however, the reasons for this risk reduction associated with coffee remain unclear.
C1 Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, FIN-00300 Helsinki, Finland.
   Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
   Inst Biomed, Helsinki, Finland.
C3 Finland National Institute for Health & Welfare; University of Helsinki
RP Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, Mannerheimintie 166, FIN-00300 Helsinki, Finland.
EM jaakko.tuomilehto@ktl.fi
CR Andersen LB, 2000, ARCH INTERN MED, V160, P1621, DOI 10.1001/archinte.160.11.1621
   Andrade-Cetto A, 2001, J ETHNOPHARMACOL, V78, P145, DOI 10.1016/S0378-8741(01)00335-X
   Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874
   ARO A, 1990, COFFEE CORONARY HEAR, V0, P71
   Barbagallo Mario, 2003, MOLECULAR ASPECTS OF MEDICINE, V24, P39, DOI 10.1016/S0098-2997(02)00090-0
   Curhan GC, 1998, ANN INTERN MED, V128, P534, DOI 10.7326/0003-4819-128-7-199804010-00003
   del Castillo MD, 2002, J AGR FOOD CHEM, V50, P3698, DOI 10.1021/jf011702q
   Ferrini RL, 1996, AM J EPIDEMIOL, V144, P642, DOI 10.1093/oxfordjournals.aje.a008975
   Goodman-Gruen D, 2001, J NUTR, V131, P1202, DOI 10.1093/jn/131.4.1202
   Hu G, 2003, DIABETOLOGIA, V46, P322, DOI 10.1007/s00125-003-1031-x
   Isogawa A, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12586-X
   Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   Keys A, 1980, 7 COUNTRIES MULTIVAR, V0, P0
   Kleemola P, 2000, ARCH INTERN MED, V160, P3393, DOI 10.1001/archinte.160.22.3393
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/nejmoa012512
   Kobayashi Y, 2000, J AGR FOOD CHEM, V48, P5618, DOI 10.1021/jf0006832
   Leitzmann MF, 1999, JAMA-J AM MED ASSOC, V281, P2106, DOI 10.1001/jama.281.22.2106
   Meier JJ, 2001, DIABETES, V50, P2497, DOI 10.2337/diabetes.50.11.2497
   Nagata C, 1998, NUTR CANCER, V30, P21, DOI 10.1080/01635589809514635
   NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186
   NEWGARD CB, 1984, DIABETES, V33, P192, DOI 10.2337/diabetes.33.2.192
   PAJAK A, 1988, WORLD HEALTH STATISTICS QUARTERLY, V41, P115
   Paolisso G, 1997, AM J HYPERTENS, V10, P346, DOI 10.1016/S0895-7061(96)00342-1
   PAOLISSO G, 1990, DIABETOLOGIA, V33, P511, DOI 10.1007/BF00404136
   PAOLISSO G, 1995, J CLIN ENDOCR METAB, V80, P1382, DOI 10.1210/jc.80.4.1382
   PIETINEN P, 1990, INT J EPIDEMIOL, V19, P586, DOI 10.1093/ije/19.3.586
   Pizziol A, 1998, EUR J CLIN NUTR, V52, P846, DOI 10.1038/sj.ejcn.1600657
   Reunanen A, 2003, LANCET, V361, P702, DOI 10.1016/S0140-6736(03)12583-4
   ROBERTSON D, 1984, AM J MED, V77, P54, DOI 10.1016/0002-9343(84)90435-2
   Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   TUNSTALL-PEDOE H, 1988, JOURNAL OF CLINICAL EPIDEMIOLOGY, V41, P105
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   Tuomilehto J, 2003, DIABETES CARE, V26, P61
   Tuomilehto J, 2003, DIABETES CARE, V26, P1770
   TUOMILEHTO J, 1990, BRIT MED J, V300, P642, DOI 10.1136/bmj.300.6725.642
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Vartiainen E, 2000, INT J EPIDEMIOL, V29, P49, DOI 10.1093/ije/29.1.49
   Yoshioka K, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12585-8
   YOUN JH, 1986, J BIOL CHEM, V261, P5960
   Zeegers MPA, 2001, INT J EPIDEMIOL, V30, P353, DOI 10.1093/ije/30.2.353
NR 44
TC 214
Z9 237
U1 0
U2 25
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 10
PY 2004
VL 291
IS 10
BP 1213
EP 1219
DI 10.1001/jama.291.10.1213
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 800XV
UT WOS:000220061900021
PM 15010442
DA 2025-04-28
ER

PT J
AU Persky, AM
   Berry, NS
   Pollack, GM
   Brouwer, KLR
AF Persky, AM
   Berry, NS
   Pollack, GM
   Brouwer, KLR
TI Modelling the cardiovascular effects of ephedrine
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE adverse events; ephedra; safety; tolerance; weight-loss
ID weight-loss; ma-huang; pharmacokinetics; tolerance; caffeine; receptor; safety; pharmacodynamics; desensitization; supplements
AB Aims Recent reports have called into question the safety of ephedra supplements especially with regards to their cardiovascular effects. The purpose of this analysis was to characterize, via pharmacokinetic/pharmacodynamic modelling, the cardiovascular effects of ephedrine, the main active ingredient of ephedra, in apparently healthy, overweight volunteers. Methods In a randomized, double-blind, crossover, placebo-controlled study, eight subjects received either placebo, 0.25, 0.5 or 1.0 mg kg(-1) ephedrine sulphate by mouth with a 7-day washout between treatments. Plasma ephedrine concentrations, heart rate and blood pressure were determined for 8 h postdose. Results The pharmacokinetics of ephedrine were best described by a one-compartment model with first-order absorption and elimination. The percentage change in heart rate was described by a linear model with a resulting slope of 0.14%.l mug(-1) (CV = 59%). The percentage change in systolic blood pressure demonstrated clockwise hysteresis, and a sigmoidal tolerance model was used to describe the data. The mean maximum predicted effect (E-max) was 53.7% (CV = 41%) with an EC50 of 107 mug-l(-1) (CV = 65%) and an inhibitory maximum (I-max) of 39.8% (CV = 60%). Tolerance developed with a mean half-life of 15 min (range 6-140 min). Conclusions This is the first study to apply a comprehensive pharmacokinetic/pharmacodynamic model to the cardiovascular effects of orally administered ephedrine. Although systolic blood pressure increases quickly after administration, the increase is nearly abolished by compensatory mechanisms.
C1 Univ N Carolina, Div Drug Delivery & Disposit, Sch Pharm, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill
RP Univ N Carolina, Div Drug Delivery & Disposit, Sch Pharm, Kerr Hall,CB 7360, Chapel Hill, NC 27599 USA.
EM apersky@nc.rr.com
FU NCRR NIH HHS [M01 RR000046, RR00046] Funding Source: Medline
CR ASTRUP A, 1993, INT J OBESITY, V17, P0
   BAUER JA, 1994, PHARM RES-DORDR, V11, P816, DOI 10.1023/A:1018917522072
   Bent S, 2003, ANN INTERN MED, V138, P468, DOI 10.7326/0003-4819-138-6-200303180-00010
   Berlin I, 2001, EUR J CLIN PHARMACOL, V57, P447, DOI 10.1007/s002280100317
   Blanck HM, 2001, JAMA-J AM MED ASSOC, V286, P930, DOI 10.1001/jama.286.8.930
   Boozer CN, 2001, INT J OBESITY, V25, P316, DOI 10.1038/sj.ijo.0801539
   Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023
   Bouchard R, 2002, CLIN J SPORT MED, V12, P209, DOI 10.1097/00042752-200207000-00003
   Broadley KJ, 1999, J AUTON PHARMACOL, V19, P335, DOI 10.1111/j.1365-2680.1999.tb00006.x
   CHOW MJ, 1985, CLIN PHARMACOL THER, V38, P318, DOI 10.1038/clpt.1985.179
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Curtis BM, 2002, MAYO CLIN PROC, V77, P45, DOI 10.4065/77.1.45
   Deedwania Prakash C, 1996, CARDIOLOGY CLINICS, V14, P229
   Dingemanse J, 1996, J CARDIOVASC PHARM, V28, P856, DOI 10.1097/00005344-199612000-00017
   Fattinger K, 1997, J PHARMACOL EXP THER, V281, P1238
   Green GA, 2001, CLIN J SPORT MED, V11, P51, DOI 10.1097/00042752-200101000-00009
   Gurley BJ, 1998, THER DRUG MONIT, V20, P439, DOI 10.1097/00007691-199808000-00015
   Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502
   Haller CA, 2002, CLIN PHARMACOL THER, V71, P421, DOI 10.1067/mcp.2002.124523
   Jacobs I, 2003, MED SCI SPORT EXER, V35, P987, DOI 10.1249/01.MSS.0000069916.49903.70
   January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871
   Kalman D, 2002, INT J OBESITY, V26, P1363, DOI 10.1038/sj.ijo.0802061
   Kanayama G, 2001, PSYCHOTHER PSYCHOSOM, V70, P137, DOI 10.1159/000056238
   KLEINJAN KJ, 1900, P48, V0, P0
   LIU YL, 1995, INT J OBESITY, V19, P678
   Ouellet DMC, 1995, J PHARMACOKINET BIOP, V23, P531, DOI 10.1007/BF02353460
   PICKUP ME, 1976, BRIT J CLIN PHARMACO, V3, P123, DOI 10.1111/j.1365-2125.1976.tb00579.x
   Samenuk D, 2002, MAYO CLIN PROC, V77, P12, DOI 10.4065/77.1.12
   Shannon JR, 1999, CLIN SCI, V96, P483, DOI 10.1042/CS19980206
   Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537
   SHI J, 1993, CLIN PHARMACOL THER, V53, P6, DOI 10.1038/clpt.1993.3
   Vansal SS, 1999, BIOCHEM PHARMACOL, V58, P807, DOI 10.1016/S0006-2952(99)00152-5
   White LM, 1997, J CLIN PHARMACOL, V37, P116, DOI 10.1002/j.1552-4604.1997.tb04769.x
   WILKINSON GR, 1968, J PHARM SCI-US, V57, P1933, DOI 10.1002/jps.2600571122
   Williams BR, 2000, MOL PHARMACOL, V58, P421, DOI 10.1124/mol.58.2.421
NR 37
TC 36
Z9 39
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD MAY 15
PY 2004
VL 57
IS 5
BP 552
EP 562
DI 10.1111/j.1365-2125.2003.02062.x
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 817HW
UT WOS:000221169600005
PM 15089807
DA 2025-04-28
ER

PT J
AU Shields, DH
   Corrales, KM
   Metallinos-Katsaras, E
AF Shields, DH
   Corrales, KM
   Metallinos-Katsaras, E
TI Gourmet coffee beverage consumption among college women
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION
LA English
DT Article
ID united-states; portion sizes; energy-intake; us; obesity; adolescents; trends; foods; men; consequences
AB Gourmet coffee beverages (GCBs) are relatively new products in the foodservice industry that consist of high-energy coffee drinks. A descriptive study was conducted to evaluate the frequency of consumption of GCBs and their energy and fat contribution to overall dietary intake in college women using a beverage questionnaire and a 3-day food diary. A convenience sample of 165 undergraduate and graduate women attending Simmons College completed a beverage questionnaire, and a subsample of 41 women completed a 3-day food diary. Mean reported GCB consumption was 2.5 times/week for the entire sample and 7 times/week for the food diary subsample. A comparison of GCB consumers and nonconsumers indicated that GCB drinkers had a 206 kcal/day higher intake (P=.250) and a 32 g higher sugar intake than nonconsumers (P<.05). A significant percentage of college women consume GCBs, which contributes additional energy and fat to dietary intake. Over time, this could potentially affect weight status.
C1 Simmons Coll, Sch Hlth Studies, Dept Nutr, Boston, MA 02115 USA.
   Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Childrens Hosp, Div Gastroenterol & Nutr, Boston, MA 02115 USA.
C3 Simmons University; Harvard University; Harvard University Medical Affiliates; Beth Israel Deaconess Medical Center; Harvard University; Harvard University Medical Affiliates; Boston Children's Hospital
RP Simmons Coll, Sch Hlth Studies, Dept Nutr, 300 Fenway, Boston, MA 02115 USA.
EM metallin@simmons.edu
CR Binkley JK, 2000, INT J OBESITY, V24, P1032, DOI 10.1038/sj.ijo.0801356
   Bowman SA, 2002, J AM DIET ASSOC, V102, P1234, DOI 10.1016/S0002-8223(02)90273-7
   DECASTRO JM, 1993, PHYSIOL BEHAV, V53, P1133, DOI 10.1016/0031-9384(93)90370-U
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   French SA, 2000, INT J OBESITY, V24, P1353, DOI 10.1038/sj.ijo.0801429
   Guthrie JF, 2002, J NUTR EDUC BEHAV, V34, P140, DOI 10.1016/S1499-4046(06)60083-3
   Guthrie JF, 2000, J AM DIET ASSOC, V100, P43, DOI 10.1016/S0002-8223(00)00018-3
   Harnack L, 1999, J AM DIET ASSOC, V99, P436, DOI 10.1016/S0002-8223(99)00106-6
   Jeffery RW, 1998, AM J PUBLIC HEALTH, V88, P277, DOI 10.2105/AJPH.88.2.277
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   Mattes Richard D, 1996, PHYSIOLOGY AND BEHAVIOR, V59, P179, DOI 10.1016/0031-9384(95)02007-1
   McCrory MA, 1999, OBES RES, V7, P564, DOI 10.1002/j.1550-8528.1999.tb00715.x
   *NAT COFF ASS US I, 2002, NAT COFF DRINK TREND, V0, P0
   Nielsen Samara Joy, 2003, JAMA (JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION), V289, P450, DOI 10.1001/jama.289.4.450
   Nielsen SJ, 2002, PREV MED, V35, P107, DOI 10.1006/pmed.2002.1037
   Nielsen SJ, 2002, OBES RES, V10, P370, DOI 10.1038/oby.2002.51
   NIELSEN SJ, 2003, JAMA-J AM MED ASSOC, V289, P1977
   Rolls BJ, 2000, J AM DIET ASSOC, V100, P232, DOI 10.1016/S0002-8223(00)00070-5
   ROLLS BJ, 1990, PHYSIOL BEHAV, V48, P19, DOI 10.1016/0031-9384(90)90254-2
   Rolls BJ, 2002, AM J CLIN NUTR, V76, P1207, DOI 10.1093/ajcn/76.6.1207
   Smiciklas-Wright H, 2003, J AM DIET ASSOC, V103, P41, DOI 10.1053/jada.2003.50000
   *STARB COFF CO, 2002, BEV RES MAN, V0, P0
   Troiano RP, 2000, AM J CLIN NUTR, V72, P1343S, DOI 10.1093/ajcn/72.5.1343s
   WEISBERG K, 2000, FOODSERVICE DIRECTOR, V13, P84
   WEISBERG K, 1999, FOODSERVICE DIRECTOR, V12, P84
   WILLETT W, 1998, NUTR EPIDEMIOLOGY, V0, P246
   Young LR, 2003, J AM DIET ASSOC, V103, P231, DOI 10.1053/jada.2003.50027
NR 28
TC 21
Z9 26
U1 1
U2 14
PU AMER DIETETIC ASSOC
PI CHICAGO
PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA
SN 0002-8223
EI 
J9 J AM DIET ASSOC
JI J. Am. Diet. Assoc.
PD APR 15
PY 2004
VL 104
IS 4
BP 650
EP 653
DI 10.1016/j.jada.2004.01.015
PG 4
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 809KE
UT WOS:000220634800025
PM 15054352
DA 2025-04-28
ER

PT J
AU Hioki, C
   Yoshimoto, K
   Yoshida, T
AF Hioki, C
   Yoshimoto, K
   Yoshida, T
TI Efficacy of Bofu-tsusho-san, an oriental herbal medicine, in obese Japanese women with impaired glucose tolerance
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article
DE Bofu-tsusho-san; impaired glucose tolerance; insulin resistance; obesity; traditional herbal medicine; visceral fat
ID body-fat distribution; beta-cell function; insulin-resistance; diabetes-mellitus; weight-loss; visceral adiposity; plasma; risk; classification; sensitivity
AB 1. In the present study, we conducted the first randomized, double-blind, placebo-controlled study of bofu-tsusho-san (BF), an oriental herbal medicine (24 mg/day ephedrine in Ephedrae Herba and an efficacy equivalent of 280 mg caffeine, judging from the phosphodiesterase-inhibitory effect of Glycyrrhizae Radix, Forsythiae Fructus and Schizonepetae Spica and another 14 crude drugs) in obese women with impaired glucose tolerance (IGT). 2. The aim of the present study was to determine whether BF was effective in decreasing visceral adiposity and insulin resistance. Eighty-one Japanese women (body mass index (BMI) 36.5 +/- 4.8 kg/m(2)) with IGT and insulin resistance (IR), who had been treated with a low-calorie diet (5016 kj/day: 1200 kcal) and an exercise regimen (1254 kj/day: 300 kcal), were randomized to receive either placebo (n = 40) or BIT treatment (n = 41) three times a day. 3. After 24 weeks treatment, the BF group lost significantly (P < 0.01) more bodyweight and abdominal visceral fat without a decrease in the adjusted resting metabolic rate (RMR), whereas the placebo group lost bodyweight (P < 0.05) and had no significant change in abdominal visceral fat. The BF group had a lower fasting serum insulin level (P < 0.05), a lower insulin area under the curve (P < 0.05) and a lower level of the homeostasis model assessment of insulin resistance (P < 0.01) compared with values before treatment. 4. We conclude that BF could be a useful herbal medicine in treating obesity with IGT.
C1 Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Endocrinol & Metab, Kamikyo Ku, Kyoto 6028566, Japan.
   Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Legal Med, Kyoto 6028566, Japan.
   Natl Hosp Org Kyoto Med Ctr, Clin Res Inst Endocrine & Metab Dis, Kyoto, Japan.
   Kyoto City Hosp, Dept Diabet & Metab, Kyoto, Japan.
C3 Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Kyoto City Hospital
RP Hioki, C (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Endocrinol & Metab, Kamikyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.
EM chioki@koto.kpu-m.ac.jp
CR Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   Baumgartner R N, 1990, EXERC SPORT SCI REV, V18, P193
   Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023
   Borch-Johnsen K, 1998, BMJ-BRIT MED J, V317, P371
   Boyko EJ, 2000, DIABETES CARE, V23, P465, DOI 10.2337/diacare.23.4.465
   CASSANO PA, 1992, AM J EPIDEMIOL, V136, P1474, DOI 10.1093/oxfordjournals.aje.a116468
   DOWLING HJ, 1995, METABOLISM, V44, P987, DOI 10.1016/0026-0495(95)90094-2
   DOWSE GK, 1991, DIABETES CARE, V14, P914
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   FULLER JH, 1980, LANCET, V1, P1373
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   Haffner SM, 1996, DIABETOLOGIA, V39, P1201, DOI 10.1007/BF02658507
   Hayashi T, 2003, DIABETES CARE, V26, P650, DOI 10.2337/diacare.26.3.650
   Kalman D, 2002, INT J OBESITY, V26, P1363, DOI 10.1038/sj.ijo.0802061
   KITAGAWA M, 1989, J NUTR SCI VITAMINOL, V35, P235, DOI 10.3177/jnsv.35.235
   KLEIN R, 1991, DIABETES CARE, V14, P914, DOI 10.2337/diacare.14.10.914
   Kuroe A, 2003, DIABETES RES CLIN PR, V59, P71, DOI 10.1016/S0168-8227(02)00177-8
   Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5
   Molnár D, 2000, INT J OBESITY, V24, P1573, DOI 10.1038/sj.ijo.0801433
   MYLLYNEN P, 1987, ACTA MED SCAND, V222, P75
   PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006
   SASAKI T, 1987, HDB PHYSL SCI, V22, P0
   Tiikkainen M, 2004, AM J CLIN NUTR, V79, P22
   TOKUNAGA K, 1983, INT J OBESITY, V7, P437
   TOUBRO S, 1993, INT J OBESITY, V17, P345
   WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604
   YOSHIDA T, 1995, INT J OBESITY, V19, P717
   YOSHIDA T, 1994, INT J OBESITY, V18, P345
   YOSHIDA T, 1995, LANCET, V346, P1433, DOI 10.1016/S0140-6736(95)92452-3
NR 31
TC 65
Z9 68
U1 0
U2 11
PU BLACKWELL PUBLISHING ASIA
PI CARLTON
PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA
SN 0305-1870
EI 
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD SEP 15
PY 2004
VL 31
IS 9
BP 614
EP 619
DI 10.1111/j.1440-1681.2004.04056.x
PG 6
WC Pharmacology & Pharmacy; Physiology
SC Pharmacology & Pharmacy; Physiology
GA 859FK
UT WOS:000224248600009
PM 15479169
DA 2025-04-28
ER

PT J
AU Petrie, HJ
   Chown, SE
   Belfie, LM
   Duncan, AM
   McLaren, DH
   Conquer, JA
   Graham, TE
AF Petrie, HJ
   Chown, SE
   Belfie, LM
   Duncan, AM
   McLaren, DH
   Conquer, JA
   Graham, TE
TI Caffeine ingestion increases the insulin response to an oral-glucose-tolerance test in obese men before and after weight loss
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE insulin resistance; type 2 diabetes; carbohydrate; proinsulin; beta cell function; hyperinsulinemia; oral-glucose-tolerance test; exercise; insulin sensitivity index
ID beta-cell function; plasma-insulin; induced impairment; intact proinsulin; diabetes-mellitus; adipose-tissue; risk-factors; exercise; resistance; fat
AB Background: Caffeine ingestion decreases the insulin sensitivity index (ISI) for an oral-glucose-tolerance test (OGTT) and decreases insulin-induced glucose disposal in lean mate subjects during a hyperinsulinemic clamp. Objective: We examined the effects of caffeine ingestion on insulin and glucose homeostasis in obese men before and after a nutrition and exercise intervention. Design: Nine sedentary, obese [body mass index (in kg/m(2)): 34.0 +/- 1.0] men who had refrained from exercise and caffeine ingestion for 48 h underwent 2 oral-glucose-tolerance tests (OGTTs). The subjects randomly received caffeine (5 mg/kg) or placebo I h before each OGTT. After a 12-wk nutrition and exercise intervention, during which time the subjects avoided dietary caffeine, the OGTTs were repeated. Results: The intervention resulted in decreases (P less than or equal to 0.05) in body weight (8.5 +/- 1.5 kg), percentage body fat (2.8 +/- 0.7%), and fasting glucose, insulin, and proinsulin concentrations and increases in the ISI for the placebo OGTT (P less than or equal to 0.05). Caffeine caused a greater (P less than or equal to 0.05) OGTT insulin response and a lower (P less than or equal to 0.05) ISI both before and after weight loss. The proinsulin-insulin ratio indicated that neither weight loss nor caffeine affected the nature of the beta cell secretion of insulin. Conclusions: A nutrition and exercise intervention improved, whereas caffeine ingestion impaired, insulin-glucose homeostasis in obese men. The results are consistent with previous findings that caffeine ingestion contributes to insulin resistance.
C1 Univ Guelph, Dept Human Biol & Nutrit Sci, Guelph, ON N1G 2W1, Canada.
C3 University of Guelph
RP Univ Guelph, Dept Human Biol & Nutrit Sci, Guelph, ON N1G 2W1, Canada.
EM terrygra@uoguelph.ca
CR ALLISON DB, 1995, DIABETES CARE, V18, P245, DOI 10.2337/diacare.18.2.245
   ANDERSON JW, 1994, MODERN NUTR HLTH DIS, V0, P1259
   Unknown -, 1994, PREVENTION OF DIABETES MELLITUS.REPORT OF A WHO STUDY GROUP, V0, P844
   ARNAUD NJ, 1993, CAFFEINE COFFEE HLTH, V0, P43
   Bergmeyer HU, 1974, METHODS OF ENZYMATIC ANALYSIS, V0, P1196
   Birmingham CL, 1999, CAN MED ASSOC J, V160, P483
   BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493
   BRODSKY EG, 1994, MODERN NUTR HLTH DIS, V0, P603
   Bruton JD, 2002, FASEB J, V16, P301, DOI 10.1096/fj.02-0481fje
   Cairney J, 1998, INT J OBESITY, V22, P584, DOI 10.1038/sj.ijo.0800632
   CAREY GB, 1994, INT J OBESITY, V18, P155
   Carey GB, 2000, J APPL PHYSIOL, V88, P881, DOI 10.1152/jappl.2000.88.3.881
   DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938
   DESPRES JP, 1989, DIABETES, V38, P304, DOI 10.2337/diabetes.38.3.304
   FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P93, DOI 10.1111/j.1600-0773.1995.tb00111.x
   Fritsche A, 2002, DIABETES, V51, PS234, DOI 10.2337/diabetes.51.2007.S234
   Graham TE, 2001, CAN J PHYSIOL PHARM, V79, P559, DOI 10.1139/cjpp-79-7-559
   Graham TE, 2001, SPORTS MED, V31, P785, DOI 10.2165/00007256-200131110-00002
   Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349
   GUTMANN OI, 1974, METHOD ENZYMAT AN, V0, P1464
   Han DH, 1998, DIABETES, V47, P1671, DOI 10.2337/diabetes.47.11.1671
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101
   Knowler William C, 2002, N ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
   LOVEJOY J, 1992, AM J CLIN NUTR, V55, P1174, DOI 10.1093/ajcn/55.6.1174
   LOWRY OH, 1993, ENZYMATIC ANAL PRACT, V0, P171
   Marshall JA, 1997, DIABETOLOGIA, V40, P430, DOI 10.1007/s001250050697
   Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462
   Nagi DK, 1998, DIABETES CARE, V21, P127, DOI 10.2337/diacare.21.1.127
   Nicklas BJ, 1996, AM J PHYSIOL-ENDOC M, V270, PE72, DOI 10.1152/ajpendo.1996.270.1.E72
   Oakes ND, 1997, DIABETES, V46, P1768, DOI 10.2337/diabetes.46.11.1768
   Obesity, 2000, WORLD HEALTH ORGAN TECH REP SER, V894, P1, DOI 10.1016/J.BBI.2016.02.019
   OLEFSKY JM, 1995, AM J CLIN NUTR, V61, P980S, DOI 10.1093/ajcn/61.4.980S
   Pascot A, 2000, DIABETOLOGIA, V43, P1126, DOI 10.1007/s001250051503
   POLONSKY KS, 1994, DIABETES, V43, P871, DOI 10.2337/diabetes.43.7.871
   REAVEN GM, 1993, J CLIN ENDOCR METAB, V76, P44, DOI 10.1210/jc.76.1.44
   REGENSTEINER JG, 1991, DIABETES CARE, V14, P1066, DOI 10.2337/diacare.14.11.1066
   Rice B, 1999, DIABETES CARE, V22, P684, DOI 10.2337/diacare.22.5.684
   Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742
   Roder ME, 1999, DIABETES CARE, V22, P609, DOI 10.2337/diacare.22.4.609
   Ross R, 2000, ANN INTERN MED, V133, P92, DOI 10.7326/0003-4819-133-2-200007180-00008
   SHIRAISHI I, 1991, DIABETOLOGIA, V34, P737, DOI 10.1007/BF00401520
   SONNICHSEN AC, 1992, METABOLISM, V41, P1035, DOI 10.1016/0026-0495(92)90134-V
   Spiller MA, 1998, CAFFEINE, V0, P97
   TANG BK, 1986, J CHROMATOGR, V375, P170, DOI 10.1016/S0378-4347(00)83706-8
   Thong FSL, 2002, CAN J APPL PHYSIOL, V27, P152, DOI 10.1139/h02-011
   Thong FSL, 2002, J APPL PHYSIOL, V92, P2347, DOI 10.1152/japplphysiol.01229.2001
   Thong FSL, 2002, DIABETES, V51, P583, DOI 10.2337/diabetes.51.3.583
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   van Nieuwenhoven MA, 2000, J APPL PHYSIOL, V89, P1079, DOI 10.1152/jappl.2000.89.3.1079
   VERGAUWEN L, 1994, J CLIN INVEST, V93, P974, DOI 10.1172/JCI117104
   Wang PW, 1997, J CLIN ENDOCR METAB, V82, P3221, DOI 10.1210/jc.82.10.3221
NR 53
TC 69
Z9 79
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JUL 15
PY 2004
VL 80
IS 1
BP 22
EP 28
DI 
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 830NB
UT WOS:000222128000005
PM 15213023
DA 2025-04-28
ER

